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We update our 1997 publication by reviewing 29 new reports of tests of magnetic fields (MFs) in
six different in vivo animal models of carcinogenesis: 2-year, lifetime, or multigeneration exposure
studies in rats or mice; and promotion/progression models (rat mammary carcinoma, rat liver focus,
mouse skin, several models of human leukemia/lymphoma in rats and mice, and brain cancer in
rats). Individual experiments are evaluated using a set of data quality criteria, and summary
judgments are made across multiple experiments by applying a criterion of rough reproducibility.
The potential for carcinogenicity of MFs is discussed in light of the significant body of
carcinogenesis data from animal bioassays that now exists. Excluding abstracts, approximately 80%
of the 41 completed studies identified in this and our previous review roughly satisfy data quality
criteria. Among these studies, the criterion for independent reproducibility is not satisfied for any
positive results but is satisfied for negative results in chronic bioassays in rats and mice and for
negative results in both promotion and co-promotion assays using the SENCAR mouse skin model.
Results of independent replication studies using the rat mammary carcinoma model were
conflicting. We conclude that long-term exposure to continuous 50- or 60-Hz MFs in the range of
0.002-5 mT is unlikely to result in carcinogenesis in rats or mice. Though results of most
promotion/progression assays are negative, a weak promoting effect of MFs under certain
exposure conditions cannot be ruled out based on available data. Key words: animal models,
carcinogenesis, EMF, electric fields, health effects, magnetic fields, toxicology. - Environ Health
Perspect 108(suppl 1):79-100 (2000).
http.//ehpnetl.niehs.nih.gov/docs/2000/suppl-1/79-100mccann/abstract.html
Previously, we reviewed 36 publications that
reported results of some 30 completed
tumorigenicity tests ofelectric and magnetic
fields (EMFs) in eight major animal model
systems and 6 studies that were in progress
(1). Since our review was published, the 6
in-progress studies have been completed,
and some 20 new reports have been identi-
fied (Table 1). More than 60 reports
describing completed studies are now avail-
able for review. The great majority of these
studies test for potential tumorigenicity of
50- or 60-Hz sinusoidal magnetic fields
(MFs) (delivered either continuously or
intermittently). More than 90% ofthe expo-
sure conditions examined in these studies
involve MFs between 1 pT and 2 mT.
Thus, an extensive database is now available
from tests of50- or 60-Hz MFs at flux den-
sities in the range of and exceeding some
environmental human exposures. In this
review we update and extend our previous
analysis. We employ a set of quality and
comparability criteria to consider whether
the results from these reports are sufficient
to justify an overall conclusion as to the car-
cinogenic potential of EMFs in animal
model systems. Assessments ofthe carcino-
genic potential ofenvironmental EMFs have
also recently been conducted by the
National Research Council (NRC) and the
National Institute for Environmental Health
Sciences (2-6).
QualityAssurance and
Reproducibility/Comparability
Criteria
Good laboratory practice (GLP) standards (7)
address the complex quality assurance (Q/A)
aspects of in vivo laboratory studies, particu-
larly long-term chronic animal bioassays. GLP
includes such aspects as standard laboratory
operating procedures and protocols for test
methods, facilities management and operating
procedures, personnel qualifications, and data
management and recordkeeping. It is not pos-
sible from examining most published reports
to determine whether a particular study con-
forms to many ofthe quality standards speci-
fied by GLP. Therefore, we consider that
studies that state they have been conducted
according to GLP provide important Q/A
information that cannot otherwise be deter-
mined. We have noted in the text and in
Table 2 those studies that indicate they have
been conducted according to GLP.
Each experiment was also evaluated
against five additional data quality objectives:
a) conformity of exposure conditions and
biologic tests to accepted protocols for a par-
ticular assay; b) sufficiency ofthe experimen-
tal details reported relative to permitting an
adequate characterization of exposure condi-
tions and biologic results; c) inclusion of
critical control experiments; d) internal
reproducibility and/or dose-response
character ofresults; and e) use ofappropriate
statistical methodology.
We have noted in the text and in Table 2
when any aspect of a study was conducted
under blinded conditions. However, we have
evaluated the significance ofthis Q/A feature
on a case-by-case basis, since there is a differ-
ence ofopinion among investigators as to the
desirability ofusing a blinded approach, par-
ticularly for pathologic evaluations (8,9).
We have also noted in the text and in
Table 2 when a study protocol included a
positive control. The importance and feasibil-
ity of including positive controls varies for
different assays. Specifically, the size and
complexity ofsome protocols, particularly
long-term chronic bioassays, preclude the
practical addition ofa positive control. Apos-
itive control, when feasible, is particularly
important to include in an assay that is rela-
tively nonstandardized or variable. We have
commented in the text on those cases in
which the addition or omission ofa positive
control contributed significantly to the
evaluation ofstudy results.
As we have previously discussed with
reference to the genotoxicity literature (10),
an important limitation in applying data
quality criteria to experiments from the pub-
lished literature is that experiments that do
not meet these criteria because ofa failure to
include sufficient information may be quite
adequate experimentally, but ifthis cannot be
determined from the information provided in
the publication, a conservative analysis must
classify them as not meeting quality criteria.
In our analysis we have attempted to at least
partially take this potential problem into
account by pointing out which experiments
failed to meet data quality criteria solely
because ofincomplete information.
Multiple experiments satisfying data
quality objectives in the same animal model
system were cross compared to determine
whether an overall positive or negative
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conclusion was justified for a particular model
system. For this second-level analysis we
considered that a result was most likely under
the conditions ofassay ifthe result could be
classified as roughly reproducible. [For an
example ofthe use ofthis approach for geno-
toxicity data, see McCann et al. (10).] The
criterion ofrough reproducibility attempts to
take into account the infrequency with which
studies are precisely replicated in the open lit-
erature. We considered that two results were
roughlycomparable ifexposure and assay con-
ditions were similar enough to conclude that
the condition ofindependent reproducibility
would most likely be satisfied were such a test
to be conducted for any ofthe studies satisfy-
ing the condition. Aspects considered in mak-
ing a judgment that protocols were roughly
similar induded rodent strains employed, dos-
ing amounts and schedules (e.g., dose ofini-
tiator in promotion studies), exposure and
end point monitoring schedules, parameters
monitored, and results in null and positive
controls. Exposures were considered roughly
similar ifflux densities employed were within
a factor of 5, iffrequencies employed were
either 50 or 60 Hz, and ifwaveforms deliv-
ered were similar in character (e.g., both con-
tinuous or both intermittent or pulsed in
experiments compared).
Clearly, decisions as to whether a
particular experiment adheres to data quality
or independent reproducibility criteria are
often not clear cut. Nor is there any clear-cut
method for unequivocally making summary
judgments concerning the positivity or nega-
tivity of an agent based on tumorigenicity
data from multiple nonidentical assay systems
and exposure conditions. Scientific judgment
must be applied, which, inevitably is
somewhat subjective.
Results
The types ofbioassays used to test EMFs for
carcinogenic potential fall roughly into two
categories. These include long-term (2-
year/lifetime or multigeneration) chronic
exposure studies aimed primarily at deter-
mining whether EMF has activity as a com-
plete carcinogen, and a variety of usually
shorter-term bioassays aimed at determining
whether EMFs have potential to modulate
post-initiation stages ofcarcinogenesis. The
29 reports available for review since our pre-
vious publication (1) are listed in Table 1.
These include 7 reports from 5 independent
research groups describing results ofsingle-
or multigeneration chronic exposure studies,
and 22 reports presenting results from 12
independent research groups conducting a
variety of bioassays focused primarily on
post-initiation stages ofcarcinogenesis.
Applying the data quality criteriaspecified
above, we present an analysis ofexperiments
presented in these 29 new reports. Results of
these reports are summarized in Table 2. We
also integrate these results with those from
our previous review (1) and offer a summary
judgment as to whether a conclusion as to the
positivity or negativity of EMFs in each
model system isjustified.
Tests ofMFs in 2-Year, Lifetime, or
Multigeneration ExposureStudies
In our previous publication (1), we identified
several 2-year or multigeneration chronic
exposure studies that were either in progress
or incompletely reported and therefore not
available for adequate review [see McCann
et al. (1) for references and discussion]. The
three studies reported as in progress have now
been completed (11-15). Studies that were
complete at the time ofour earlier review but
that could not be evaluated because theywere
available only in preliminary or abstract form
have now appeared in more complete form
(16,17). We briefly review and assess results
reported in these seven new reports.
The studies conducted by the National
Toxicology Program (NTP) using F344 rats
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Table 2.Tests of magnetic fields in carcinogenesis bioassays.
Rodent strain Initiator/(promoter) EMF exposurea Comments on quality criteria Results reported by author Reference
Tests aimed primarily at detecting initiators
F344/N rats and
B6C3F1 mice (male
and female, 100 per
sexgroup)
F344/DuCrj rats
(male and female,
48 per sex group)
F344 rats (female,
50 pergroup)
C57B1/6 mice
(females, 380 per
MF-exposed group)
CFW mice(male and
female). Numbers of
animals exposed to
the MF = 3(1stgen.);
44(2nd gen.); 92 (3rd
gen.)
60-Hz, 2 pT, 0.2 mT, or 1 mT
(18.5 hr/d, 7 d/wkfor 106
wk); or 60-Hz, 1 mT(inter-
mittent: 1 hr on/i hr off,
18.5 hr/d, 7 d/wk, 106wk)
50-Hz, 0.5 mT, 5 mT
22.6hr/d for2 yr
60-Hz, 2 pT, 20 pT, 200 pT,
or 2 mT(20 hr/d, 2 yr
beginning 2 d before birth)
60-Hz, 1.41 mT, circularly
polarized, 18.5 hr/d. Expo-
sure began at4wk and
ended at natural death
(-29mo)
60-Hz, 25 mT(23 hr/d)
GLP; independent audits of pathology
data, specimens, and tables
Histopathologic analysis limited to
tissues exhibiting macroscopic signs
of disease
Independent analyses to monitor
animal health, and Q/Aaudits ofthe
exposure systems and pathology data
and diagnoses; both the exposure and
the histopathologic analyses were
conducted under blinded conditions
GLP; internal and external peer
reviews ofthe histopathologic
diagnoses; the exposure and histo-
pathologic analyses were conducted
under blinded conditions
Unusual experimental design; limited
information provided on some critical
aspects ofthe experimental protocol
and pathologic analysis
Tests aimed primarily at detecting agents thataffect postinitiation stages
Equivocal evidence of carcinogenic
activityb in male rats based on
increased incidence ofthyroid gland
C-cell neoplasms in male rats exposed
to 2 pTand 0.2 mT MFs (p<0.01)
Negative. A statistically significant
(p< 0.05) increase in fibroma ofthe
subcutis in male ratswas considered
not biologically significantwhen
compared to historical controls
Negative
Negative for lymphoid cell neoplasms
Positive. Statistically significant
increase in lymphoma incidence in
third-gen. animals exposed to the
MF compared to unexposed controls
of carcinogenesis
Ratmammarygland
Outbred rats
(females, - 40-50
per group)
Sprague-Dawley
rats (females, 99
pergroup)
Sprague-Dawley rats
(females, 99 per
group)
Sprague-Dawley
rats (females, 99
pergroup)
Sprague-Dawley
rats (females, 60
pergroup)
MNU (50 mg/kg,
i.v., lx/wkfor
3wk)
DMBA(5 mg/rat,
i.g., 1x/wkfor 4
wk)
DMBA(10mg/rat,
i.g., lx)
DMBA(5 mg/rat,
i.g., 1x/wkfor 4
wk)
DMBA
(7 mg/rat, i.g.,
lx)
50-Hz, - 20 pT ac ordc;
3 hr/d for 15 mo; MF
exposure began 2 d
afterthe first injection
50-Hz, 100 pT, 24 hr/d,
7 d/wkfor 91 d
50-Hz, 100 pT, 24 hr/d,
7 d/wkfor27 wk
50-Hz, 10 pT, 24 hr/d,
7d/wkfor91 d
50-Hz, 0.25 and 0.5 mT,
15 secon/i5 sec off, 19-21
hr/d for 21 wk beginning
1 wkfollowiing DMBA
Insufficient information on the
design of the exposure system
and the rat strain employed
No histopathologic analysis; all
phases ofthe study conducted under
blinded conditions; exposure para-
meters validated by independent
audit; exposure system patterned on
an NTP-recommended protocol
All phases ofthe studyconducted
under blinded conditions; exposure
parameters independently
validated at regular intervals
Partial histopathologic analysis;
exposure and biochemical measure-
ments conducted under blinded
conditions.
Use of a rat substrain with a high
propensity to develop mammary
tumors spontaneously; no vehicle
control group; malignant status of
tumors notconfirmed histologically
Positive. Increased incidence ofadeno-
carcinoma in animals exposed (under
24-hr lightconditions) to MNU and ac
fields compared to rats exposed to MNU
alone (p<0.05); decreased latency in
rats exposed (under 12 hr light/12 hr
dark)to MNU and acfields compared
to rats exposed to MNU alone (p<0.05);
and decreased latency in rats exposed
(under 24-hr lightcondition) to MNU
and dcfields compared to rats exposed
to MNU alone(p<0.05)
Positive. Increased incidence of palpable
mammarytumors in rats exposed to the
MFcompared to sham-exposed animals.
At necropsy, increased incidence of
macroscopically visible tumors (83%
vs 62% at91 d, p<0.05)
Positive. Increased incidence of palpable
mammary tumors in MF-exposed rats
compared to sham-exposed controls at
wk 13, 14, 15, 17, and 18(p<0.05). At
necropsy, increased incidence of macro-
scopicallyvisible histologicallyverified
tumors (p<0.05)
Negative
Negative
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Table 2. Continued.
Rodent strain Initiator/(promoter)
Sprague-Dawley
rats (females,
100 per group)
DP
4
Sprague-Dawley DI
rats (females, i.g
100 pergroup) 4
Sprague-Dawley DI
rats (females, i.g
100 per group)
Mouse skin-promotion
SENCAR mice Di
(females, 56 per nn
group; nontumor to
biomarkers for
tumor promotion
were examined in
an additional 24
mice pergroup)
Mouseskin-co-promotion
SENCAR mice DI
(females, 56 per m
group; nontumor wl
biomarkers for +/
tumor promotion or
were examined in
an additional 24
mice pergroup)
SENCAR mice Dl
(sex unspecified, m
47-48 pergroup) (PI
m
wl
fo
K2 mice (female U\
transgenics over- wl
expressing ODC and
their nontransgenic
littermates, 21-22
pergroup)
SENCAR mice DI
(number pergroup m(
not reported) (Tl
m
MBA (5 mg/rat,
g., 1x/wk for
wk)
IMBA(2 mg/rat,
g., 1x/wk for
wk)
MBA (10 mg/rat,
g., lx)
MBA (10
mol/mouse,
)pical)
MBA (10 nmol/
iouse, topical, 2
ik prior to TPA);
/-TPA (1.04, 2,
4.2 pg/wk)
IMBA (10 nmol)/
iouse, topical/
'MA, 0.3 pg/
iouse/wk for 23
ikbeginning1 wk
)lowing DMBA)
IV(200 J/m2, 3x/
k)for 10.5 mo
tMBA (10 nmol/
iouse, topical)/
'PA(0.25 mg)/
louse, 2x/wk)c
EMF exposurea Comments on quality criteria Results reported by author Reference
50-Hz, 0.1 mT or 0.5 mT; Negative, but high control incidences of (33,34)
or 60-Hz, 0.1 mTfor 18.5
hr/d, 7 d/wkfor 13 wk
50-Hz, 0.1 mTor 0.5 mTfor
18.5 hr/d, 7 d/wk for 13 wk
GLP; magnetic field characterizations
independently verified; pathology
slides, data records, and tables
verified by independent evaluation
and reviewed, under blinded condi-
tions, bythe NTP Pathology Working
Group; complete studyaudit by an
independent Q/A contractor
50-Hz, 0.1 mT or0.5 mT;
or60-Hz, 0.1 mTfor 18.5
hr/d, 7 d/wkfor26 wk
60-Hz, 2 mT, 6 hr/d, 5 d/wk
for23 wk
60-Hz, 2 mT, 6 hr/d, 5 d/wk
for 23 wk
(33,34)
(33,35)
(54,55)
(52,54,55)
(53)
(56)
(57)
mammary tumors precluded a determin-
ation of possible magnetic field effects
Negative
Negative
Negativefor skin tumors and nontumor
biomarkers
GLP
GLP
60-Hz, 2 mT, 6 hr/d, 6d/wk
for23wk
50-Hz, continuous: 0.1 mT;
intermittent: 1.3, 13, and
130 pT, each applied in suc-
cession for 20 min followed
by a 2 hr pause. Both condi-
tions applied 24 hr/d for
10.5 mo except for UV ex-
posure time and cage and
room cleaning (2 hr/wk)
60-Hz, continuous: 0.2 mT
and 2 mT; intermittent(30
minon/30 min off): 2 mT.
Both conditions applied 7
hr/d, 7 d/wk for43 wk
Inadequate detail in data presentation
Insufficient information provided for
analysis
Negative for skin tumors and nontumor
biomarkers
Negative.
Positive. Statistically significant
(p <0.015) increase in rate of onsetof
macroscopically detectable tumors
in both transgenic mice exposed to UV
and MFs compared to UV controls
Positive. 0.2 mT, continuous: 20%
increase in tumor incidence at43 wk;
22% increase in total tumors/papillomas
and tumors/papillomas per animal at43
wk. 2 mT, intermittent: small increase in
tumors/papillomas peranimal between
10-20 wk. Authors do not indicate
whether resultswere statistically
significant
Mouse lymphoma
C57BI/6 mice
(females, 190-380
pergroup)
Ionizing radiation
(cobalt 60): 3.0 Gy,
4.0 Gy, or 5.1 Gy,
delivered as frac-
tionated doses at
4weekly intervals
beginning at4wk
60-Hz, 1.41 mT, circularly
polarized, 18.5 hr/d. Expo-
sure began at4wk and
ended at 29 mo
GLP; internal and external peer reviews
ofthe histopathologic diagnoses;
exposure and histopathologic
analyses conducted under blinded
conditions
Negative for a variety oflymphoid/
leukemia neoplasms.
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Table 2. Continued.
Rodent strain Initiator/(promoter) EMF exposurea Comments on qualitycriteria Results reported byauthor Reference
Swiss-Webster
mice (male and
female, 75-89
per sex group)
Ratleukemia transplant
F344 Fischer rats
(males, 126/group)
F344 Fischer rats
(males, 18/group)
DMBA (35 ,ug/
mouse, lx,
s.c. at birth)
LGL leukemia
cells (2.2 x 107/rat,
i.p.) injected on
the first d of MF
exposure
LGL leukemia
cells (2.2 x 107 or
2.2 x 106cells/rat,
i.p.) injected on
the first d of MF
exposure
50-Hz, 1 mT (3 hr/d, 6 d/wk
for 16 wk beginning at 14 d
of age
60-Hz, 1 mT, 20 hr/d,
7 d/wk for 18 wk
60-Hz, 1 mT, continuous
or intermittent (3 min
on/off), 20 hr/d, 7 d/wk
for 22 wk
Lymphoma/leukemia-prone mouse strains-transgenic systems
TSG-p53 mice 60-Hz, 1 mT, 18.5 hr/d
(hemizygous for the for 23 wk
p53 null-allele)
(males and females,
30/sex group)
Ep-pim-1 mice ENU (25 mg/kg,
(males and females, lx, i.p.) one d
30/sex group) prior to MF
exposure
Ep-pim-1 mice
(females,
~ 100/
group)
Lymphoma/leukemia-prone mouse strains-
AKR mice
Ratbrain
F344/N (females,
50/group)
C57B1/6 mice
(females, 190-
380 per group)
ENU (5 mg/kg
i.v. on d 18 of
gestation)
Ionizing radiation
(cobalt 60): 3.0Gy
4.0 Gy, or 5.1 Gy,
delivered as frac-
tionated doses at
4weekly intervah
beginning at 4wk
60-Hz, 2 pT, 200 pT, 1 mT
(continuous, 18.5 hr/d for
23 wk); or 60-Hz, 1 mT
(intermittent, 1hr on/i hr
off, 18.5 hr/d for 23wk)
50-Hz, 1 pT, 100 pT, or 1 mT
(continuous, 20 hr/d) up to
18 mo; and 50-Hz, 1 mT
(pulsed, 15 min on/off)
-leukemia-prone mice
12-Hz, 6 pT; or460-Hz,
pulsed. Both exposures
for 30 min, 2x/wk for
5 generations
60-Hz, 2 pT, 20 pT,
200 pT, or 2 mTfor 16
mo beginning 48 hr
after ENU treatment
60-Hz, 1.41 mT,
y, circularly polarized, 18
hr/d. Exposure began at
4 wk and ended at 29 mo
Incomplete data presentation
GLP; progress of experiments periodi-
cally reviewed by an independent
auditor; positive control group
receiving 5 Gywhole body irradiation
included
GLP; characteristics of magnetic field
exposure validated bythe National
Institute of Standards and Technology
GLP
Necropsies performed only on animals
exhibiting clinical signs of disease;
incomplete analysis due to autolysis or
other causes; exposure and pathology
conducted under blinded conditions;
histopathology independently evalu-
ated; positive control (ENU) included
Incomplete characterization of exposure
and other aspects of study protocol;
high spontaneous incidence of
leukemia in control
GLP; variability in tumor indidence
among control groups; exposure,
clinical observations, and pathologic
evaluations conducted under blinded
conditions; exposure system and
pathology evaluations validated by
independent audit; pathology slides
reviewed under blinded conditions;
positive control (TPA) included
GLP; internal and external peer
reviews ofthe histopathologic diag-
noses; exposure and histopathologic
analyses conducted under blinded
conditions
Statistically significant (p<0.01) increase
in metastatic infiltration by lymphoma
cells into liver in the MF-exposed group
compared to sham-exposed controls.
No statistically significant differences
between MF-exposed and sham-
exposed groups in thymic lymphoma
incidence at 32 wk
Negative. Disease parameters (body
weight, splenomegaly) monitored for 18
wk. Hematologic, morphologic, and
and histopathologic parameters moni-
tored for 10-11 wk by repeated bleeding
(18 animals pergroup) and serial
sacrifice (108 animals per group)
In the group exposed to intermittent
fields, enhancement ofthe onset of
leukemia in the group injected with
2.2 x 107 cells only(p <0.01). Hemato-
logic parameters monitored for 14wk
wk (2.2 x 107 injected cell groups) or 16
wk (2.2 x 106 injected cell groups)
Negative
Negative. lymphoma incidence in males
exposed to 1 mT continuous fields signi-
ficantly reduced (p <0.05) compared
to controls
Negative. Statistically significant
increase in a lethal nontumor end point:
a transgene-dependent renal glomerular
disease in 1 mT(continuous) MF-
exposed group compared to sham-
exposed controls
Negative for leukemia
Negative
Negative
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(79)
(77)
(77)
(83)
(85)
(133)
Babbitt et
al. (see dis-
cussion of
the RAPID
Working
Group (3)
Abbreviations: d, day; ENU, N-ethyl-N-nitrosourea; gen., generation; J, joule; mo, month; PMA, phorbol 12-myristate 13-acetate; TPA, 12-0-tetradecanoylphorbol-13-acetate wk, weeks; yr, year; -, approxi-
mately. lac fields are sinusoidal unless otherwise noted. bAn evidence category used by the NTP. Equivocal evidence ofcarcinogenic activity is demonstrated by studies that are interpreted as showing a
marginal increase of neoplasms that may be exposure related (11). C1his veryhigh dose ofTPA is most likely atypographical error in Byus et al. (57).
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and B6C3F, mice set the standard for
long-term chronic exposure bioassays (18).
These assays are designed primarily to
determine whether an agent can act as a com-
plete carcinogen, but since a variety ofneo-
plasms develop spontaneously in the rodent
strains used, agents that affect promotion or
progression may also be detected. In the NTP
protocol, relatively large numbers ofanimals
ofboth sexes (usually 50 animals persex expo-
sure group) are exposed chronically to a test
agent and are monitored over a 2-year period
for survival, body weight, and clinical signs of
disease. At death or termination ofthe experi-
ment, animals are evaluated by complete
necropsyandhistopathologic examination.
In the NTP MF exposure study
(11-13,19), larger-than-standard-size groups
(100 animals per sex exposure group) ofrats
and mice were employed in an effort to
increase the sensitivity ofthe assay for the
detection ofpossibly weak MF effects. As
shown in Table 2, F344/N rats and B6C3F1
mice ofboth sexes were exposed (18.5 hr/day,
7 days/week) to continuous 60-Hz MFs of2
pT, 0.2 mT, or 1 mT, or to intermittent 60-
Hz, 1-mT fields (1 hr on/1 hr off). Exposure
began when the animals were 6-7 weeks old.
The experiment also included sham-exposed
controls (100 animals per group) for each
species and sex.
This study was conducted in accordance
with GLP, and in addition, independent
audits of pathology data, specimens, and
tables were conducted (11-13). A prelimi-
nary 8-week toxicity study was also con-
ducted using the same set ofexposures as
employed in the 2-year chronic bioassay to
determine a baseline for standard toxicologic
parameters (20). Though statistically signifi-
cant increases in liver weight and liver-to-
body weight ratios in female rats of all
exposure groups were noted, the study did
not identify any significant toxic effects.
Investigators noted that increased liverweight
is a common finding in animals exposed to
xenobiotics. Liver weight and liver-to-body
weight ratios were not included in reports of
the carcinogenesis study (11-13).
Analysis of the carcinogenesis bioassay
results conducted byNTP (11-13) includes a
comprehensive histopathologic evaluation
and statistical analyses primarily to determine
whether MF exposure resulted in statistically
and biologically significant effects on tumor
incidence. A limitation ofthe NTP protocol
is that it does not include a serial sacrifice
component and thus does not permit analysis
of tumor latency, which, along with tumor
incidence, can be an indicator that an agent
can affect neoplastic development.
Five evidence categories ofcarcinogenic
activity are employed by the NTP to
summarize the strength of the evidence
observed in each experiment [e.g., see the
description of these categories in NTP
(11)]. The selection-of-evidence category is
based primarily on histopathologic and sta-
tistical considerations, though in difficult
cases other factors may play a part. Such fac-
tors include bioassay conditions such as Q/A
issues and evidence external to the bioassay
such as structure-activity correlations or
results ofgenetic toxicology tests.
Statistical analyses were conducted by the
NTP study investigators to test for differences
between control and MF-exposed groups in
mortality and tumor incidence across a large
number oftumor types. For the most part,
significant differences were not observed. The
few differences that were noted were: a) early
mortality (p < 0.05) of the 1-mT-exposed
group ofmale mice; b) increased incidences
of thyroid gland C-cell adenomas in the
2-pT- and 0.2-mT-exposed groups ofmale
rats (p < 0.05), C-cell carcinomas in the 2-
gT-exposed group of male rats, and com-
bined C-cell adenomas and carcinomas in
both the 2-pT- and 0.2-mT-exposed groups
ofmale rats (p < 0.01); and c) decreased inci-
dences ofmononuclear cell leukemia in male
rats (p < 0.05) and several tumor types in
mice (p < 0.01). The decreases in tumor inci-
dences were considered by investigators
unlikely to be related to MF exposure [see
Boorman et al. (13) and McCormick et al.
(12) for discussion].
Investigators concluded that the increased
incidences ofthyroid gland C-cell neoplasms
in male rats constituted equivocal evidence of
carcinogenic activity, based on the evidence
categories applied by the NTP (11,13). As
noted by investigators, however, the statisti-
cally significant increases observed were con-
sistent with the frequency offalse positives
expected to occur by chance because ofthe
large number oftumor types over which sta-
tistical tests were performed. Thus, the
increase in thyroid gland C-cell neoplasms
quite possibly reflects random variability in
tumor distribution rather than indicating a
biologic effect ofMFs.
Investigators indicate that the statistically
significant early mortality noted in male mice
exposed to 1 mT continuous fields did not
appear to be accounted for by any clinical
toxicity or specific tumor types (11,12), but
the difference is not further discussed.
Yasui et al. (16) exposed groups of 48
male and female F344/DuCrj rats beginning
at 5 weeks of age to sham, or 50-Hz,
0.5-mT and 5-mT fields for 22.6 hr/day for
2 years (Table 2). Body weight and mortal-
ity were monitored throughout the experi-
ment. Neoplastic end points were tumor
incidence across a number oftumor types at
terminal sacrifice, hematopoietic effects
determined by examination of peripheral
blood smears from tail bleeding at 52 and 78
weeks, and the age-specific prevalence ofsev-
eral tumor types detectable by palpation or
moribund appearance prior to mortality.
Investigators reported that there were no
statistically significant differences between
exposed and sham-exposed groups that were
considered to be ofbiologic significance. The
incidence ofone tumor type, fibroma ofsub-
cutaneous (s.c.) tissue, was elevated in male
rats exposed to 5 mT MFs (p < 0.05), but the
increase was considered by investigators not
to be biologically meaningful, as it was within
the historical control range previously
observed in their laboratory for this tumor
type. With the qualification that the
histopathologic analysis was apparently only
carried out on tissues that exhibited macro-
scopic signs ofdisease, this study appears to
satisfyquality criteria.
The Yasui et al. study (16) is the only
long-term chronic exposure study available
other than the NTP study discussed above
(11,13) that examined F344 male rats. It is
therefore of interest to compare the two
studies, as both tested overlapping ranges of
MF intensities. Selected parameter values
from the two studies are summarized in
Table 3. As shown, at the termination ofboth
studies, mean body weights were similar.
Survival percentages are somewhat higher for
all groups in the Yasui et al. study. This over-
all difference in mortality could be due to
dietary differences or to the fact that different
substrains ofF344 rats were used in the two
studies (F344/N rats in the NTP study and
F344/DuCrj rats in the Yasui et al. study).
Also, as shown in Table 3, whereas the overall
percent of neoplasms and the percent of
benign neoplasms were similar in the two
studies, the incidence ofmalignant neoplasms
in the Yasui et al. studywas less than halfthat
observed in the NTP study. This disparity
could also be due to substrain differences and
possibly also to the more limited histopatho-
logic analysis conducted by Yasui et al., as
indicated above. Note also that neither the
increased incidence offibroma ofs.c. tissue
reported by Yasui et al. (16) nor the
increased incidence of thyroid C-cell ade-
noma and carcinoma reported by the NTP
(11,13) were observed in the other study.
Thus, these two studies provide independent
evidence that strongly suggests that MFs
under the conditions tested do not affect
tumor incidence in male F344 rats.
Mandeville et al. (14) exposed groups of
50 female F344 rats beginning 2 days prior to
birth to 60-Hz sham (< 0.02 pT), 2-pT, 20-
gT, 200-jT, and 2-mT fields for 20 hr each
day for 2 years (Table 2). In addition to
sham-exposed controls, controls housed in a
different room from exposed and sham-
exposed groups were included. Body weight
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Table 3. Values of selected parameters from two 2-year cancer bioassays of effects of magnetic field exposures in male F344 rats.a
Yasui et al. (16) NTP( 11,13)
Parameters Sham 0.5 mT S mT Sham 2 pT 0.2 mT 1 mT(cont.) 1 mT(int.)
Mean bodyweights at 104-105weeks (g) 440-450b 440 450b 440 450b 484 467 473 478 476
Survival at 2 years (%) ~ 73C 82C 78C 57 46 47 48 59
Overall tumor incidence
% of animals with neoplasms 100 100 100 100 98 98 100 98
% of animals with benign neoplasms 100 100 98 99 97 97 98 94
% of animals with malignant neoplasms 33 29 23 65 59 61 65 58
Specific tumor types (%)
Fibroma of s.c. tissue 4 10 191 12 8 9 13 12
Thyroid C-cell adenoma and carcinoma 17 21 13 16 31e 30e 25 22
Abbreviations: cont., continuous; int., intermittent. aStudies were conducted by the NTP (1 1,13) and Yasui et al. 16). bEstimated from Figure 1 in Yasui et al. 16). cEstimated from Figure 2 in Yasui et al.
(16). dp0.05. ep< 0.01.
and survival were monitored throughout the
study and full necropsies and histopathologic
evaluations of all tissues were performed on
all animals under study. Neoplastic parame-
ters reported are tumor incidence at the end
ofthe study and cumulative tumor incidence
during the course of the study. A number of
statistical tests were performed to compare
tumor incidence in exposed and control
groups (both sham-exposed controls and
room controls) and to determine whether a
trend in incidence over the different dose
groups could be discerned. Investigators
reported no statistically significant effects of
MF exposure on survival or tumor incidence.
With one qualification (discussed below),
this study appears to conform to quality crite-
ria. Both the exposure and the histopathologic
analyses were performed under blinded condi-
tions. The study was also subjected to a Q/A
procedure performed by an independent
pathology laboratory during the course ofthe
experiment and the pathology results were
reviewed (also under blinded conditions) by a
panel that included independent pathologists
(14). It should be noted, however, that sur-
vival ofthe sham-exposed controls and sur-
vival of two ofthe MF exposure groups were
significantly lower than that ofthe room con-
trol group (32-38% vs 60%). In the NTP
study (11), the survival offemale F344 rats at
104 weeks was 61-69% over all groups, simi-
lar to survival of room controls in the
Mandeville et al. (14) study. Thus, a caveat to
the conclusion that the Mandeville et al. (14)
study satisfies quality control criteria must be
some concern that either uncontrolled or con-
founding factors may have produced early
mortality in the sham-exposed controls and in
two of the MF-exposed groups. Curiously,
this difference did not appear to affect the ter-
minal tumor incidence rates, which were simi-
lar in all groups. This discrepancy in mortality
rates was not addressed by Mandeville et al.
(14) or the EMF Research and Public
Information Dissemination Program
(RAPID) Working group (3-5).
Since the F344 rats employed in the
Mandeville et al. (14) study are the same
strain and substrain ofanimal utilized by the
NTP in their EMF studydiscussed above (11)
and were obtained from an NTP facility, and
the MF exposure ranges in both studies over-
lap, the two studies provide independently
replicated evidence that MFs under the condi-
tions tested do not affect tumor incidence or
mortality rates in female F344 rats.
The mouse lymphoma study of Babbit
et al. (15) is unique because ofits size (2,660
female C57B1/6 mice), its use of a lifetime
model employing both uninitiated and
ionizing-radiation-initiated animals, and its
completeness with respect to a detailed
histopathologic analysis of tissues relevant to
lymphoma/leukemia end points. Tumors
observed in these tissues were enumerated
and classified according to the Pattengale sys-
tem (21). This system identifies five classes of
lymphoid neoplasms (follicular center cell,
plasma cell, immunoblastic, small lympho-
cytic, lymphoblastic) on the basis ofmorpho-
logic and immunologic criteria (21). The
analysis of Babbitt et al. (15) included these
five classes as well as related tumor types.
The Babbitt et al. (15) study conforms to
quality control criteria. The study conformed
to GLP and both the exposure and pathology
phases of the study were conducted under
blinded conditions. The pathology phase of
the study was also subjected to extensive
internal and external peer review. The
Babbitt et al. (15) study thus provides a sta-
tistically sensitive, high quality assay ofboth
the initiating and promoting potential of
MFs with respect to thymic lymphoblastic
lymphomas, which occur in relatively young
animals, as well as a variety ofother lymphoid
neoplasms that occur in aged mice. Here we
discuss the portion of the study aimed at
detecting effects ofMF exposure on otherwise
uninitiated animals, and in subsequent sec-
tions we discuss the tests for possible effects
of MF exposure on animals pre-exposed to
ionizing radiation.
Babbitt et al. (15) exposed 380 female
C57B1/6 mice to 60-Hz, 1.41-mT (circularly
polarized) MFs 18.5 hr/day from 4 weeks of
age to natural death (median age at death of
room controls was 29 months). Controls
included 190 sham-exposed mice and a group
of380 unexposed mice housed in a separate
room. Body weight, mortality, and clinical
signs were monitored throughout the study.
At death or terminal sacrifice all animals were
necropsied and a complete histopathology
report was generated on the tissues examined.
Detailed tumor incidence and mortality
data are provided for total lymphoid neo-
plasms and for the subtypes mentioned
above. No indication ofa statistically signifi-
cant increase in tumor incidence was noted
for any lymphoid tumor end point.
Investigators note, however, that visual
inspection ofhazard plots (the percent ofani-
mals dying with lymphoma present at various
time points during the course of the study)
for several of the end points tabulated (total
lymphomas, B-cell lymphomas, histiocytic
sarcomas, and all hematopoetic neoplasms)
suggests these tumors appeared earlier in the
MF-exposed animals. The differences noted,
however, are not statistically significant.
Fam and Mikhail (17) have reported
results of a three-generation MF exposure
study several times in abstract form [see
McCann et al. (1) for list ofreferences] and
most recently in peer-reviewed format. The
study employed CFW male and female mice
and 23 hr/day exposure to high-intensity
MFs of 60 Hz, 25 mT. The first generation
consisted of 1 male and 2 female mice for
each of the exposure and control groups
(i.e., a total of 6 mice). These animals were
continuously exposed to the MF during
mating, gestation, and birth of the second-
generation of animals. To derive the third
generation, 4 males and 8 females were cho-
sen from the second-generation MF-exposed
group and 2 males and 4 females from the
second-generation control group. Then, as
before, these animals were continuously
exposed to the MF during mating, gestation,
and birth of the third generation. The total
numbers of mice in the MF-exposed group
evaluated in each generation were 1 male
and 2 females in the first generation, 16
males and 28 females in the second
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generation, and 44 males and 48 females in
the third generation. The total numbers in
the control group were, respectively, one
male and two females, 12 males and 8
females, and 16 males and 25 females.
After sacrifice, all animals were autopsied
and tissue sections were taken from a number
oforgans to determine the presence oflym-
phoid neoplasms. The presence of non-
lymphoid tumors was notrecorded. Results are
reported in tabular form for second and third
generation animals. A nonstatistically signifi-
cant increase in early and advanced lymphoma
was observed in thesecond generation animals,
and ahighlystatisticallysignificant (p < 0.001)
resultwas observed in thethirdgeneration.
This report is unique in that the intensity
ofMF exposure far exceeds that employed in
any ofthe other available long-term chronic
studies. The next highest intensity employed
was 5-fold less, 5 mT, in the Yasui et al. (16)
study discussed above. In addition, the posi-
tive result reported by Fam and Mikhail (17)
is highly statistically significant. However,
there are a number ofaspects of this study
that are either unclear or do not meet quality
control criteria, which brings into question
thevalidity ofthe findings. A number ofcon-
cerns are discussed in the report of the
RAPID Working Group (3). For example,
the multigeneration protocol is particularly
unusual in its use ofsingle progenitors, lim-
ited information is provided on critical
aspects ofthe experimental protocol (particu-
larly the protocol for animal sacrifice), several
ofthe pathology figures presented in the arti-
cle as representative ofmouse leukemia infil-
trates appeared instead to be age-related
lymphocytic infiltrates, and control mice were
not sham-exposed but were exposed to 500
mG of60-Hz stray MFs.
In summary, the study of Fam and
Mikhail (17) is inadequately presented and
does not conform to quality control criteria.
Although it would not be appropriate to
completely discount the study, it also would
be inappropriate to consider it further with-
out significant clarification and follow-up
from the investigators.
Summary. Four of the five long-term
chronic exposure studies reviewed above
provide convincing evidence that fields of
intensities ranging from 2 jiT to 5 mT do
not result in an increase in tumor incidence
in male or female F344 rats orB6C3F, mice
or in female C57B1/6 mice. With the excep-
tion ofspecific caveats noted in the discus-
sion above, these studies were of high
quality and three (11-15) were conducted
according to GLP. In addition, exposure
ranges tested in particular studies overlapped
those of at least one of the other studies,
providing some evidence ofreproducibility
for the negative results. As discussed above,
there is insufficient evidence at this time
either to completely discount or to accept as
valid the strongly positive but clearly flawed
study ofFam and Mikhail (17).
Tests ofMagneticFields inAssays
Designed to DetectEffects on Post-
initiation Stages ofCarcinogenesis
Tests of magnetic fields using the rat
mammary carcinoma modeL Though a variety
ofanimal models ofbreast cancer are available
(22), the most commonly used model contin-
ues to be the 7,12-dimethylbenz[a]anthracene
(DMBA) promotion model in rats developed
more than 30 years ago [for recent review see
Russo and Russo (23,24)]. In our previous
report (1), we reviewed eightpublished reports
ofcompleted studies and one in progress
report. The completed studies included posi-
tive results reported by Loscher and col-
leagues [L6scher et al. (25), Baum et al. (26),
Mevissen et al. (27), and Beniashvili et al.
(28)]. We concluded that these positive
studies suggested the possibility ofa promot-
ing effect ofMF exposure at the flux densities
tested (20 1sT-100 gT). We cautioned, how-
ever, that despite statistical significance,
results were not highly statisticallysignificant,
that there was considerable variability in
tumor incidence rates among unexposed
groups, and that the sensitivity of the
DMBA/mammary system to modulation by
many dietary and other endogenous factors
implied that caution should be applied in
evaluating the results (1).
Seven new reports are now available for
analysis (29-35). The conditions under
which these newly available experiments were
conducted and the results obtained are in
Table 2. For details and discussion ofearlier
experiments, see our previous review (1).
Each newexperiment is discussed below.
The new study of Beniashvili and
colleagues (29) includes some variation in
lighting conditions not present in their earlier
report but appears to include conditions that
approximately replicate those in the group's
earlier positive report (28). In particular, as
shown in Table 2, groups ofapproximately
40-50 outbred female rats (strain unspecified)
were injected with the initiator N-methyl-N-
nitrosourea ([MNU] 50 mg/kg, intravenous
[i.v.], lx/week for 3 weeks). MF exposure (50
Hz, -20 PT, ac or dc, 3 hr/day) was initiated
2 days after the first MNU injection and con-
tinued for 15 months. The first appearance of
mammary tumors was determined by weekly
palpation, and mammary adenocarcinoma
incidencewasconfirmed histologically.
This study (29) satisfies most but not all
quality control criteria. The biologic aspects
ofthe protocol appear to conform to prior
experience with MNU induction of
mammary tumors in rats, most critical
controls are included, and appropriate
statistical methodology is employed. Though
a dose-response curve is not reported, the
appearance of palpable mammary tumors
over time is recorded and the same MF expo-
sure conditions were previously employed in
similar experiments using different lighting
regimes (28), thus roughly approximating
replication conditions. The report, however,
does not provide sufficient experimental
details concerning the design ofthe exposure
system and the rat strain employed. In
addition, a sham-exposed control group was
not included.
In the group's earlier report (28), MNU
apparently was administered only once; the
mammary tumor incidence reported in
MNU-treated rats was 59%, with a mean
latency period of74 days. In the more recent
report, these values are 32% and 166 days.
Thus, tumor incidence appears to be lower
and the latency period considerably longer in
the more recent report despite using 3 times
the amount ofMNU used in the earlier study.
The significance ofthis apparent inconsistency
is uncertain. The discrepancy could be due to
an error ofomission in the protocol descrip-
tion in the group's first report. In the pub-
lished literature there is considerable
variability in the i.v. dose ofMNU required to
elicit comparable mammary tumor incidence
in the same rat strains [e.g., see Rose and
Mountjoy (36) and VanderPloeg et al. (37)],
so the apparent variability in sensitivity to
MNU in the two reports (28,29) from the
Beniashvili group may not necessarily be of
concernwith respect to studyquality.
The primary value ofthe Anisimov et al.
(29) report with respect to this review is the
extent towhich it maybe considered areplica-
tion ofthe positive results reported previously
by the same group (28). The condition using
a 12-hrlight/12-hr dark illumination schedule
and a 3-hr daily MF exposure in the more
recent study (29) roughly duplicates condi-
tions reported previously (28). Differences are
the apparent discrepancy in the reported
number ofMNU treatments discussed above
and some difference in the duration ofthe
experiments [24 months (28) compared to 15
months (29)]. Previously, the group reported
a statistically significant (p < 0.05) increase in
tumor incidence in groups exposed to MNU
and to either ac or dc fields compared to the
group exposed only to MNU. In the current
report (29), though there are increases in the
incidence ofmammary adenocarcinomas in
both the ac and dc groups compared to the
group exposed onlyto MNU, the increases are
not statistically significant. Significant
increases were only observed in the MF-
exposedgroups when the experimentwas con-
ducted under 24-hrlightingconditions. In the
group's earlier report (28), apparently
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significant decreases in the mean latency
period were also reported for the two MF-
exposed groups pretreated with MNU com-
pared to the group exposed only to MNU. In
the current report (29), the MNU-treated ac-
exposed group exhibits a significantly shorter
latency (p < 0.05) than the MNU-only group,
thus reproducing the earlier result. However,
the dc-exposed group does not show any
decrease in latency. Thus, the results presented
in these two reports differ in some respects.
The most recent study does, however, support
the group's previous findings with respect to
an apparent enhancement effect ofac fields on
the rate ofdevelopment ofMNU-induced
mammary adenocarcinoma.
The Loscher group recently presented the
results of two studies (32,38) intended in
part to test the reproducibility oftheir earlier
findings (25,26) that continuous exposure of
female Sprague-Dawley rats to 50-Hz, 100-
pT MFs for 13 weeks results in a) a signifi-
cant increase in tumor growth as determined
by palpation (25); b) a significant increase in
tumor volume determined at autopsy (26);
and, c) astatisticallysignificant increase in the
incidence ofadenocarcinomas (26).
In the first of these two studies (32),
investigators report a statistically significant
(p < 0.05) increase in mammary tumor inci-
dence in MF-treated rats compared to sham-
exposed DMBA-treated controls as
determined by palpation from 9 weeks
through the termination ofthe study at 13
weeks. A significant increase (p < 0.05) in
tumor incidence was also reported based on
the incidence of macroscopically visible
tumors determined at autopsy. This experi-
ment appears to be thoroughly described and
meets quality control criteria except for the
omission of a histopathologic analysis. All
phases ofthe study were conducted under
blinded conditions, exposure parameters were
validated by independent audit, and the
exposure system was patterned on an NTP-
recommended protocol.
In the second study, Thun-Battersby et al.
(38) exposed 99 female rats to sham or 50-
Hz, 100-,uT MFs 24 hr/day, 7 days/week for
27 weeks. A single dose of DMBA (10
mg/rat, intragastric [i.g.]) was administered
after 1 week of exposure to the MF. The
number, volume, and location ofmammary
tumors were monitored by palpation for 27
weeks. At necropsy, macroscopically visible
tumors were confirmed histologically, and
neoplastic lesions were classified. The study
conforms to quality control criteria. In addi-
tion, all aspects ofthe study were conducted
under blinded conditions, and, as in the pre-
vious study, exposure parameters were inde-
pendently monitored at regular intervals.
The results reported by Thun-Battersby
et al. (38) again confirm the group's earlier
observations (25,32) of a statistically
significant (p < 0.05) increase in the incidence
ofpalpable mammary tumors in MF-exposed
rats at 13 weeks compared to sham-exposed
controls. The earlier report ofan increase in
tumor volume on necropsy at 13 weeks (26)
is also approximately replicated (results were
statistically significant at 12 weeks [p <
0.05]), although Thun-Battersby et al. (38)
determined tumor volume during this time
period by palpation, since their experiment
was not terminated until 27 weeks. Finally,
the statistically significant increase in adeno-
carcinomas at 13 weeks reported by Baum et
al. (26) was not observed at 27 weeks by
Thun-Battersby et al., though this more
recent report did observe a nonstatistically sig-
nificant increase in the incidence ofadeno-
carcinomas at 27weeks.
The Loscher group (31), using the same
experimental protocol employed in their ear-
lier studies (25,27), report that continuous
exposure offemale Sprague-Dawley rats (99
per group) for 91 days to 50-Hz, 10-pT MFs
does not result in a statistically significant
increase in the incidence ofmammary tumors
when the MF-treated group is compared to
DMBA sham-exposed controls. The exposure
phase ofthis study and biochemical measure-
ments (e.g., melatonin) were conducted
under blinded conditions, and the studysatis-
fies quality control criteria except that a
histopathologic analysis was performed on
only some tumors.
Interpretation of the combined results
now available from the Loscher group is com-
plex. The most completely reported positive
experimental results prior to the reports dis-
cussed above (32,38) are from two studies
(25-27). The first ofthese studies (25,26)
employed 100-pT MF exposures and
reported tumor incidence (proportion ofani-
mals with tumors) on the basis ofresults of
weekly palpation (25) or histopathologic
examination (26). These two analyses indi-
cated that a statistically significant (p < 0.05)
difference in tumor incidence between MF-
exposed and sham-exposed DMBA-treated
rats was observed at 13 weeks based on results
ofpalpation (25), but that asignificant differ-
ence was not observed when incidence was
calculated based on numbers of tumors
observed in a histopathologic examination of
animals from the same study examined at 13
weeks (26). Instead, Baum et al. (26)
observed: a) a statistically significant increase
in median tumor volume between MF-
exposed and sham-exposed animals, suggest-
ing an effect of MF exposure on tumor
growth but not on overall tumor incidence;
and b) a significant increase in the incidence
ofanimals with histologically confirmed ade-
nocarcinomas, suggesting an effect of MF
exposure on tumor progression. The second
study (27) employed 50-pT MF exposures
and also reported statistically significant
increases in tumor incidence based on palpa-
tion during the course ofthe 13-week study
and macroscopically visible tumors atautopsy.
The recent studies ofMevissen et al. (32)
and Thun-Battersby et al. (38) discussed
above are partially consistent with the results
ofthese two earlier studies. First, astatistically
significant increase in tumor incidence at 13
weeks on the basis ofpalpation and the num-
ber of animals with macroscopic tumors
observed at autopsy (also at 13 weeks) was
reported in the replication study (32); this is
roughly consistent with the original observa-
tion ofLoscher et al. (25) and Mevissen et al.
(27). However, statistically significant differ-
ences in tumor volume between MF-exposed
and sham-exposed animals based on measure-
ments at autopsy at 13 weeks were not
observed in the replication study (32), in
contrast to the report of Baum et al. (26)
[Mevissen et al. (32) did not determine the
incidence ofadenocarcinomas histologically].
In the more recent 27-week study of
Thun-Battersby etal. (38), the palpation result
at 13 weeks is again confirmed. However, as
this experiment was not terminated until 27
weeks, autopsy and histopathology results can-
not be directly compared with earlier 13-week
experiments. Thun-Battersby et al. (38) did,
however, estimate tumor volume during the
course oftheir experiment by palpation, and
report a statistically significant (p < 0.05)
increase in tumor volume in MF-exposed rats
compared to sham-exposed controls at 12
weeks. Thus, while the recent reports of
Mevissen et al. (32) and Thun-Battersby etal.
(38) do not stricdy replicate all ofthe group's
original findings, they do roughly replicate the
observations based on palpation.
Ekstrom et al. (30) used female Sprague-
Dawley rats (60 per group) to test for a possi-
ble enhancing effect on the rate of
development of mammary tumors induced
by DMBA (7 mg/rat, i.g.) from chronic expo-
sure (21 weeks) to 50-Hz intermittent (15 sec
on/15 sec off) MFs (250 pT and 500 pT).
No statistically significant differences in
latency, tumor incidence, tumors per tumor-
bearing animal, or total tumor weight were
observed in either ofthe MF-exposed groups
compared to the DMBAcontrol.
This study does not conform to all quality
control criteria and thus is difficult to inter-
pret or compare to other studies using the
DMBA-mammary tumor model. As dis-
cussed by investigators, a Sprague-Dawley rat
substrain with a high propensity to develop
mammary tumors spontaneously in the
absence of DMBA was used. Since a vehicle
control group was not included in the study,
it is not clear to what extent tumors observed
were spontaneous or DMBA induced. In
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addition, the malignant status of tumors
observedwas notconfirmed histologically.
Recently, the NTP completed studies
(33-35) to independently test the repro-
ducibility ofthe positive results reported by
the Loscher group discussed above. Three
experiments were conducted. The experi-
mental conditions of each ofthese experi-
ments are summarized in Table 2. Two
13-week studies and one 26-week studywere
conducted involving chronic exposures to
50- or 60-Hz MFs of 0.1 mT and 0.5 mT.
All three studies are thoroughly documented
and satisfy quality control criteria.
Experiments were conducted according to
GLP; the MF characterizations were inde-
pendently verified; pathology slides, data
records, and tables were verified by indepen-
dent audit and reviewed under blinded con-
ditions by the NTP Pathology Working
Group. On completion ofthe study, a com-
prehensive retrospective study audit was con-
ducted by an independent Q/A contractor.
In the first 13-week study, very high
incidences (93%) ofmammary tumors in the
DMBA-treated control rats prevented deter-
mination ofpossible effects ofMF exposure
on tumor incidence at 13 weeks. In the sec-
ond 13-week study, the dosing of DMBA
was decreased so that tumor incidence in
DMBA-treated sham-exposed controls was
more consistent with results reported by the
Loscher group (43% in the NTP study com-
pared to 34-62% in the positive studies of
the Loscher group).
The results ofthe second 13-week study
(33,34) did not demonstrate any increase in
tumor incidence in either MF-exposed group
(50 Hz, 0.1 mT and 0.5 mT) compared to
sham-exposed controls determined either by
palpation over the course ofthe 13 weeks,
macroscopically at necropsy, or histologically.
The mean area per carcinoma determined at
necropsy was slightly larger (8-16%) in both
MF-exposed groups compared to the
DMBA-treated sham-exposed controls. This
small increase was notstatisticallysignificant.
The 26-week study (33,35) was
conducted using a single dose ofDMBA (10
mg/rat) prior to MF exposure in contrast to
the fractionated dose protocol used previously.
This exposure protocol resulted in a tumor
incidence (as determined by palpation) at 13
weeks ofapproximately 65% and at 26 weeks
of100%. This experiment was appropriate for
examining possible effects ofMF exposure on
tumor latency and on growth rate butwas not
appropriate for comparing tumor incidence at
26 weeks because ofhigh tumor rates in the
DMBA-treated sham-exposed controls. The
weekly palpation data do not demonstrate any
apparent increase in the rate oftumor growth
in the MF-treated animals over the course of
the experiment. In fact, fewer tumors and
fewer tumors per rat were observed in all
exposed groups compared to controls. The
mean area per carcinoma, however, deter-
mined at necropsy suggests a slightly larger
though not statistically significant tumor vol-
ume (9-24% greater than controls) in all
three MF-exposed groups compared to the
DMBA-treatedsham-exposed controls.
Results ofthe second 13-week study and
the 26-week study are validly comparable
with the positive results reported by the
Loscher group. Positive results reported by
the Loscher group were the following:
* in animals exposed to 100 pT MFs, a sta-
tistically signiflcant increase in tumor
incidence persisting throughout 13- and
27-week protocols determined by palpa-
tion;
* a statistically significant increase in tumor
incidence at the termination ofeither 13-
or 27-week experiments as determined by
macroscopicallyvisible tumors at autopsy;
* a statistically significant increase in the
incidence ofadenocarcinomas at the ter-
mination ofthe 13-weekexperiment; and
* a statistically significant increase in tumor
volume at the termination ofthe 13-week
experiment ofBaum et al. (26), an obser-
vation not found in one replication by the
same group (32) but approximately repli-
cated in asecond study (38).
The first three points are clearly contra-
dicted by the NTP study, whereas the final
point is not clearly contradicted.
Tests ofmagneticfields using the mouse
skin modeL Although the use oftransgenic
models ofepidermal carcinogenesis in mice is
increasing [e.g., Holden et al. (39); recent
reviews by Brown et al. (40) and Arbeit
(41)], the two-stage DMBA/12-O-tetrade-
canoylphorbol-13-acetate (TPA) model in
SENCAR mice is still in wide use [reviewed
by DiGiovanni (42); discussed in our previ-
ous review (1)]. For more recent research
attempting to elucidate the complex factors
involved in the development ofneoplasia in
this model, see Shibata et al. (43) and
Kiguchi et al. (44) on the involvement of
transforming growth factor-a (TGF-oc);
Rundhaug et al. (45) on the time-course of
changes in expression ofTGF-a, epidermal
growth factor, and other protein factors;
Larcher et al. (46) on the possible involve-
ment ofH-ras in the control ofangiogenesis;
and Battalora et al. (47) on the possible role
ofCa+2 in promotion.
In our previous report (1) we reviewed 6
published reports of tests of MFs in the
DMBA mouse skin model and four abstracts
providing preliminary data [see McCann
et al. (1) for references]. These 10 reports
included several peer-reviewed studies that
reported suggestive (48,49) or positive (50)
effects ofMF exposure, and one abstract that
also reported positive results (51). We
concluded that results ofpromotion experi-
ments in the mouse skin systemwere substan-
tially negative, but that there was some
suggestion oflate effects associated with MF
exposure in co-promotion assays.
Since our earlier review (1), completed
reports (52-55) are now available for three of
the four abstracts, one new study has
appeared (56), and another abstract from the
Byus group is available (57). All but one
(54,55) ofthese new studies examined only
the co-promotion potential of MFs. The
study ofDiGiovanni et al. (54,55) primarily
examined co-promotion but included an
experiment on promotion (Table 2). The
promotion experiment, using the SENCAR
mouse, employed DMBA (2.56 pg) as initia-
tor and chronic exposure (6 hr/day, 5
days/week) to 60-Hz, 2-mT continuous
fields. Results were negative, confirming pre-
vious similar reports (58,59).
Sasser et al. (52) and DiGiovanni and
colleagues (54,55) recently published the
detailed results oftheir study, which we pre-
viously discussed based on preliminary
reports [see McCann et al. (1) for references
and discussion]. The Sasser and DiGiovanni
study (52,54,55) was well controlled and was
also conducted according to GLP. The study
employed SENCAR mice in the DMBA/
TPA two-stage model and found no co-
promotional effects from exposure ofmice
(56 animals per group) to 60-Hz, 2-mT MFs
(6 hr/day, 5 days/week) at any time up to 23
weeks across three TPA doses (1.04 pg/week,
2 jig/week, and 4.2 pg/week). Though several
aspects ofthe Sasser/DiGiovanni protocol
(52,54,55) are not identical to the earlierpos-
itive experiment ofStuchly et al. (50) [see
McCann et al. (1) for our earlier review of
the Stuchly et al. study], the two experiments
are comparable. As discussed by investigators,
differences include the use ofa diet lower in
fat content by Sasser et al. (52) (4.5% com-
pared to 11%), which is expected to result in
a somewhat lower incidence ofskin tumors in
TPA-treated controls. This decreased sensitiv-
ity may be partly responsible for the large dif-
ference in tumor incidence rates in
TPA-treated controls at comparable time
periods in the two studies. Thus, the percent-
age ofsham-exposed mice with tumors at 16
weeks among animals treated with 1 jig TPA
weekly in the Stuchly et al. (50) experiment
was about 90%, whereas in the experiment of
Sasser et al. (52) the comparable percentage
in sham-exposed controls treated with 1.04
jig/wk was about 20%. On the basis ofpilot
studies, Sasser et al. (52) and DiGiovanni
et al. (54) thus selected significantly higher
weekly doses of TPA than those used by
Stuchly et al. (50) to achieve tumor incidence
rates in TPA-treated controls in the same
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response range as those in the positive study
and to accommodate a sensitive statistical
analysis. Thus, despite some differences
between the two studies, the negative experi-
ment of Sasser et al. (52) and DiGiovanni
et al. (54) may be said to approximately repli-
cate conditions of the earlier positive
experiment ofStuchly et al. (50).
The apparently positive results reported
by Stuchly et al. in 1992 (50) must be viewed
within the context ofthe entire body ofwork
presented bythe Stuchlyand McLean groups.
In our previous review (1), we evaluated
reports from these groups available at that
time (49,50,58-60). McLean et al. (60), in
abstract form, reported that the initial obser-
vation of transient co-promotional effects
reported by Stuchly et al. (50) was not repro-
duced in two subsequent experiments. Since
our review, more detailed results of these
replication experiments have been published
(53). These more detailed results appear to
satisfy quality control criteria and provide
data that confirm the absence ofan increase
in tumor incidence in MF-exposed mice at
23 weeks. Although limited data are provided
in this new report ofresults at the more cru-
cial earlier time period, McLean et al. (53)
indicate in their discussion that the apparent
transient effect on promotion from weeks 12
to 18 observed by Stuchly et al. (50) may
have been due to inherent variability in the
response of the SENCAR mouse in the
two-stage assay.
Kumlin et al. (56) employed a transgenic
hybrid strain ofmice overexpressing ornithine
decarboxylase (ODC), and nontransgenic lit-
termates. Mice had coat colors varying from
white to dark brown and their ages at the ini-
tiation of the study varied from 6 to 9
months. Investigators attempted to minimize
possible effects of these variations by using
similar age and color distributions in each
experimental group. Chronic exposure to
ultraviolet (UV) light (200J/m2, 3x/week for
10.5 months) was employed to induce skin
tumor development. Possible co-initiation
and co-promotion were examined both in
transgenics and nontransgenic littermates by
exposing UV-treated mice to either MFs or to
sham fields. MFs were applied 24 hr/day for
10.5 months and were either continuous (50
Hz, 0.1 mT) or intermittent (50 Hz, 1.3, 13,
and 130 ,uT, each applied in succession for 20
min followed by a 2-hr pause).
Investigators report that macroscopic skin
tumors appeared earlier (measured by tumor
incidence and numbers of tumors per ani-
mal) in both transgenic and nontransgenic
mice exposed to both UV and either contin-
uous or intermittent MFs comnpared to the
corresponding groups exposed only to UV.
These results were statistically significant
only for the transgenic group (p < 0.015).
Investigators also report an apparent increase
in the incidence ofskin tumors greater than
8 mm in diameter in MF- + UV-exposed
animals at the termination ofthe study (46
weeks) but do not indicate whether this
result was statistically significant.
This study employed a relatively new skin
tumor model system developed in the investi-
gator's laboratory (61) and it is thus not
directly comparable to other skin tumor
studies testing MFs, all ofwhich used younger
and different strains ofmice (most often SEN-
CAR) in the DMBA/TPA skin tumor model.
With the exception ofthe inadequate detail in
data presentation discussed below, leading to
difficulties in interpreting the results, the
study conforms to most quality control
criteria andcould be ofinterest.
The study is difficult to evaluate for
several reasons. First, the key results (tumor
incidence as a function oftime) are presented
only as values summed over the continuously
and intermittently exposed groups. Second,
investigators failed to provide data on num-
bers ofanimals with multiple lesions. Third, a
positive control was not included; this would
have been helpful to assist in validating the
new assay. Finally, a puzzling feature of the
study, as discussed by investigators, is the
apparent lack of any increase over UV-
exposed controls in the terminal incidence of
histologicallyverified papillomas or squamous
cell carcinomas in MF- + UV-exposed trans-
genic or nontransgenic animals compared to
the 2- to 3-fold increase in epidermal cysts in
the MF- + UV-exposed transgenics (56).
In abstract form, Byus and Ma (57)
reported the results ofstudies to replicate and
extend earlier experiments that were also pub-
lished in abstract form (51). These studies
examined the possible co-promoting effects of
60-Hz MFs in the SENCAR two-stage mouse
model. Details ofthe experimental protocol
and MF exposures are in Table 2. We dis-
cussed the earlier studies from this group pre-
viously (1). To our knowledge neither of
these studies has been published in a more
detailed format. Because ofthe limited infor-
mation presented, and inconsistencies possibly
due to typographic errors in the abstracts, it is
notpossible to evaluate these studies.
Summary. Results of tests for possible
promoting or co-promoting effects of MFs
are now available from five independent
research groups. All but one of the co-
promotion studies employed the DMBA
model in SENCAR mice. Among studies
using the SENCAR mouse model, the pro-
motion studies (48,59) discussed in our pre-
vious review (1) as well as the more recent
study ofDiGiovanni et al. (54) are substan-
tially negative, although Rannug et al. (48)
reported a marginally statistically significant
dose trend for intermittent exposure groups.
To our knowledge, there has been no attempt
to replicate these suggestive findings.
However, recently the Rannug et al. (48)
work was reviewed by the RAPID Working
Group (3), which pointed out several limita-
tions in the study such as the lack ofcontrol
over switching transients and also the ques-
tionable appropriateness oflumping results
from different exposure levels.
All co-promotion studies were conducted
using long-term exposure to 60-Hz, 2 mT
fields. Results of these studies are predomi-
nantly negative. Experiments from two
research groups (52,53) strongly suggest
that 60-Hz, 2 mT MFs do not co-promote
development of skin tumors in SENCAR
mice in the DMBA/TPA two-stage model at
any time up to 23 weeks after the initiation
of exposure. These negative studies contra-
dict the transient co-promotion effect at
week 18 initially reported by Stuchly et al.
(50). One positive result (p < 0.03) that we
discussed previously (1) has not yet been
tested by replication. In this experiment, an
increase in progression to malignancy was
observed in SENCAR mice exposed to 60-
Hz, 2 mT MFs for 52 weeks in a
DMBA/TPA two-stage co-promotion assay
in which TPA was applied for the first 23
weeks ofthe experiment (49).
Testofmagneticfields usinganimalmod-
els ofleukemia andlymphoma. A number of
murine models of lymphoma/leukemia are
available. For recent reviews, see Uckun (62)
and Pattengale (21,63). Though many fac-
tors, such as the complex role played by
viruses in murine neoplasia, complicate the
determination ofthe relevancy ofthese mod-
els to human cancer, some lymphoma/
leukemias in mice have similarities to the
diverse collection of neoplasms grouped
under this general heading in humans
(21,64,65). Table 4 illustrates a number of
correlates between murine and human forms
oflymphoma/leukemias in six relevancy cate-
gories: pathologic presentation (e.g., frequency
ofoccurrence, severity, time course, metastatic
characteristics); immunohistochemistry; mech-
anisms (e.g., physiologic, cellular, or molecular
changes associated with neoplasia); cytogenetic
changes associated with lymphomagenesis or
leukemogenesis; oncogene involvement; and
agents or conditions that modulate induction,
promotion, orprogression.
Several models oflymphoma/leukemia in
mice have been suggested as possibly relevant
to human B-CLL (66-70). One ofthe mod-
els described below that has been used to test
EMF, the large granular lymphocyte (LGL)
rat leukemia transplant model, has been pro-
posed as an appropriate model for human
T-CLL (71). The pathologic characteriza-
tions of the common forms ofleukemia in
children, acute lymphocytic leukemia, and
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Table 4. The human relevance of murine leukemia/lymphoma models.
Relevancy category
Pathologic presentation (e.g., frequency
of occurrence, severity, time course,
metastatic characteristics)
Immunohistochemistry
Mechanisms (e.g., physiologic, cellular,
or molecular changes associated with
neoplasia)
Cytogenetic changes associated with
lymphomagenesis
Oncogene involvement
Agents orconditions that modulate
induction, promotion, or progression
Example
Almost all types of human lymphomas have also been observed in mice
The distribution of lymphoma tumortypes is roughly similar in humans and mice
There are age similarities between murine lymphoblastic T-cell lymphoma/leukemia and
the analogous childhood and young adultT-cell neoplasms in humans
The B/T ratios of lymphomas in human adults and older mice are similar (3-4:1)
lnterleukin-6 is involved in the pathogenesis of murine plasmacytoma and human multiple myeloma
Similar tumorantigen markers have been observed in both humans and mice
Both malignant CD5 B cells in NZB mice and human B-CLL cells express interleukin-10 mRNA
Similar cytogenetic changes have been observed in certain lymphomas in humans and mice:
in radiation-induced thymic lymphomas in C57BL/6 or SCID mice and in human populations at
high risk for lymphoma
in mouse plasmacytomas and human Burkitt's lymphoma
in follicular centercell lymphomas in SJlmice and in human germinal center lymphomas
in CD5 B-cell chronic lymphocytic leukemia in NZB mice and in human B-CLL
Although oncogene involvement is known to be important in lymphomagenesis in both mice
and humans, relationships between specific oncogenes and pathogenic outcomes are not
necessarily the same in both species
Among the human lymphomas, only Burkitt's is known to involve c-myc, whereas in mice c-myc
has been associated with plasmacytomas
Other examples where the same oncogene leads to different neoplasms in mice and humans
An increased risk of lymphoma/leukemia is associated with radiation exposure and certain chemicals,
especially immunosuppressive cancerchemotherapeutic agents in both humans and mice
A majority ofapproximately 10 carcinogens tested in long-term rodent bioassays that were
associated with an increased incidence of lymphoma or leukemia in humans also induced
related neoplasms in rats or mice.
acute myeloid leukemia, are quite different
from that ofCLL. The growth ofboth these
childhood leukemias can be studied in
immune-deficient mice by transplantation
(72,73). It has also been suggested by
Pattengale (21) that there are similarities
between early-appearing murine lymphoblas-
tic T-cell lymphomas and analogous child-
hood leukemia/lymphomas. These T-cell
neoplasms are a primary end point in the
Kaplan split-dose ionizing radiation model in
mice (74), which has been used to test EMF
(15,75). Results ofthese experiments are dis-
cussed below. Some soft tissue tumors and
lymphomas that occur in p53-deficient mice
are also similar to some tumors of childhood
(76). A model using transgenic mice het-
erozygous for the p53 null allele has recently
been used to test EMF (77); results are
described below.
It should be noted that whereas the
responsiveness ofmodels involving the mouse
mammary gland and mouse skin to a wide
variety of promoters is well established [see
McCann et al. (1) for discussion and exam-
ples], this is not the case for the
lymphoma/leukemia promotion/progression
models. This lack ofvalidation represents a
serious limitation in interpreting the signifi-
cance of results obtained from tests of EMF
in these systems, especially the significance of
negative findings. To the extent that the
capability ofindividual systems used to test
for possible effects of EMF have been
demonstrated to detect agents affecting
promotion or later stages ofcarcinogenesis,
this is indicated below in the discussion of
each system.
Among the reports involving leukemia or
lymphoma end points included in our previ-
ous review (1), only two studies were avail-
able as completed reports in peer-reviewed
journals (75,78). As both of these studies
were criticized on issues involving methodol-
ogy or sensitivity [see McCann et al. (1) for
discussion], the negative results reported can-
not be considered reliable. The remainder of
the studies reviewed could not be fully
assessed, as they were either in progress or
reported only in abstract form [see McCann
et al. (1) for references].
Since our earlier review (1), a considerable
amount of new information has become
available. First, the studies that were in
progress at the time of our earlier review have
been completed. These studies include a) an
assay involving the split-dose ionizing radia-
tion model in mice (15) that has been com-
pleted but not yet published in journal
format; b) a large, multi-experiment LGL rat
leukemia transplant assay (79,80), portions
ofwhich have appeared in journal format
(81,82); and c) a transgenic assay in Ep-pim-
1 mice (83). Second, a negative lymphoma
promotion study in pim-1 mice and mice
heterozygous for p53, which at the time of
our earlier review was available only in
abstract form, has now been published in
more complete form (77). Third, two
studies we have not previously reviewed, one
using a DMBA promotion assay in
mice (84) and another examining effects of
MF exposure on a strain ofleukemia-prone
mice (85) have been identified.
Below, we discuss the eight reports sum-
marizing the results ofthese prevously unre-
viewed studies (15,79-85).
All assays reviewed are designed primarily
to detect effects ofEMF exposure on post-
initiation stages of carcinogenesis. Some
assays use initiating agents prior to EMF
exposure such as ionizing radiation or N-
ethyl-N-nitrosourea (ENU). Other assays
such as the rat leukemia transplant model use
neoplastic cell lines (cells that are already ini-
tiated) and measure the rate of neoplastic
development in cell transplant recipients.
Others use rodent strains with enhanced sen-
sitivity for the spontaneous development of
certain neoplasms, such as mice heterozygous
for p53. We discuss each of these three
general types ofassays separately.
LYMPHOMA IN MICE PRE-EXPOSED TO
INITIATING AGENTS. Exposure ofC57Bl mice
to fractionated doses ofionizing radiation
results primarily in the induction ofthymic
lymphomas, most ofwhich are lymphoblastic
lymphomas. These tumors represent neo-
plasms of immature thymocytes at various
stages ofT-cell development (21,86). As indi-
cated above, it has been suggested that there
may be some similarities between early-appear-
ing murine lymphoblastic T-cell lymphomas,
the primary end point in this model system,
and the analogous childhood and young adult
T-cell neoplasms in humans (21).
As we previously discussed (1), the
mechanism oflymphomagenesis induced by
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split-doses of ionizing radiation in mice is
incompletely understood. Recent research
continues to explore the involvement of
genetic changes (87-89), oncogenes (90),
epigenetic factors (86), immunologic
defenses (91), and the RadLV virus (92) in a
complex process that appears to include a
variety ofcell types comprised ofthymic and
pre-thymic cells as well as other bone-marrow
derived cells (93-95). With only one excep-
tion ofwhich we are aware [the study by
Chen and Berenblum on urethane (96)], this
system has not been used previously to study
effects ofpromoters on tumor development.
As shown in Table 2, Babbitt et al. (15)
exposed groups of 190-380 female C57B1/6
mice to four weekly doses ofgamma irradia-
tion totaling 3.0 gray (Gy), 4.0 Gy, or 5.1 Gy
beginning at 4 weeks of age. MF exposure
was initiated simultaneous with the first
gamma irradiation treatment. For each radia-
tion dose, groups of mice were either sham-
exposed (190 mice) or exposed to 60-Hz,
1.41-mT (circularly polarized) MFs (380
mice). Exposure was for 18.5 hr/day and con-
tinued up to 29 months. In addition to MF
sham-exposed controls (190 per group) at
each ofthe three radiation doses, the experi-
ment also included an unirradiated sham-
exposed control group (190 mice), an
unirradiated MF-exposed group (380 mice),
and a group of380 mice housed in a separate
room that were unexposed to either gamma
radiation or MFs.
In an earlier section, "Tests of Magnetic
Fields in 2-Year, Lifetime, or Multigeneration
Exposure Studies," we discussed results ofthis
study obtained for animals unirradiated with
ionizing radiation and exposed or unexposed
to the MF. In that section we also discussed
the quality assurance aspects of this study.
Here we address results obtained for the irra-
diated groups. As for the unirradiated groups,
body weight, mortality, and clinical signs
were monitored throughout the study. At
death or terminal sacrifice all animals were
necropsied and a complete histopathology
analysis was conducted including classifica-
tion oflymphoid cell neoplasms as discussed
above. A number ofstatistical comparisons
were made between groups exposed to both
ionizing radiation and the MF and each cor-
responding ionizing radiation control group.
Comparisons were made for total lymphoid
neoplasms and for each individual lymphoid
tumor type. No statistically significant differ-
ences were observed with respect to the MF.
The sensitivity of the study is relatively
high because of its quality and use of large
numbers of animals in each test group.
Although only one MF exposure level was
employed, the use of test groups exposed to
three different levels of gamma irradiation
provides some internal measure ofconsistency
as well as the possibility of discerning a
radiation dose-response trend.
Analysis of this study is complicated to
some extent by the lack of prior history with
the system with respect to the effectiveness of
known promoters and also by the fact that in
animals exposed to gamma irradiation, the
time course oflymphoma induction is com-
plex. The primary effect ofsplit-dose irradia-
tion in the Kaplan model is to increase the
incidence of early (up to about 300 days)
lymphomas. Thus, experiments using the
Kaplan model are usually terminated at
approximately 1 year. However, Babbitt et al.
(15) extended their experiment for the life-
time ofthe animals (approximately 2.5 years).
Thus, in control groups exposed to different
levels of ionizing radiation, a relatively early
increase was observed in the percentage of
mice dying with lymphoma present, and in
aged mice a second wave ofincrease in lym-
phomas was observed. Possible effects ofMF
exposure on the rate of development of
radiation-induced lymphomas were deter-
mined at various time points after initiation
ofexposure, up to 2.5 years. Since there was
not a provision for serial sacrifice in this
study, tumor incidence could not be deter-
mined precisely prior to terminal sacrifice.
However, since, as indicated by investigators,
lymphoblastic lymphoma was very likely the
cause ofdeath for animals dying during the
first year ofthe studywith this tumor present,
the incidence value employed (death with
lymphoma present) is most likely a valid
reflection oflymphoma incidence.
When death with lymphoma present was
compared for MF-exposed animals and corre-
sponding radiation controls using only data
obtained during the first year of the experi-
ment, no statistically significant effects ofMF
exposure were apparent. Thus, the percent of
animals dying with lymphoma present were,
for the 0-, 3.0-, 4.0-, and 5.1-Gy exposed
groups respectively; 0, 0.53, 5.3, and 25% for
the controls; and 0, 1.1, 6.1, and 19% for the
MF-exposed groups. Statistically significant
effects of MF exposure ofgamma-irradiated
groups were also not observed at time periods
longer than 300 days, up to 2.5 years. This
was true for all lymphomas combined and for
the subtypes examined, which were lym-
phoblastic, lymphocytic, and combined B-cell
lymphomas. Also, no significant effects were
seen for histiocytic sarcoma.
Shen et al. (84) exposed groups of male
or female Swiss-Webster mice (75-89 per sex
group) to 50-Hz, 1-mT MFs (3 hr/day, 6
days/week for 16 weeks beginning at 14 days
of age) after a single treatment with DMBA
(35 pg/mouse, sc) shortly after birth. At 32
weeks ofage, the experiment was terminated
and all animals were subjected to histo-
pathologic examination. Neoplastic end
points examined were premalignant, early, or
advanced thymic lymphoma reported as
tumor incidence and metastatic infiltration in
the liver and spleen of mice with advanced
lymphoma, which were also reported as
incidence values.
The Shen et al. (84) report roughly
satisfies data quality criteria, with some
reservations. The specific model system
employed has, to our knowledge, not been
used previously, but data on group survival
and tumor incidence in negative controls
(two sham-exposure groups, one with and
one without DMBA treatment) suggest that
there was no excessive toxicity and that
tumor incidences were within a range
permitting valid comparisons.
With respect to the major end point,
tumor incidence, the investigators report no
significant effect. However, the results were
less clear for some secondary end points. The
investigators report that, for the most severe
category of metastatic infiltration in liver,
when data for males and females were pooled,
comparison of incidence in MF-exposed and
sham-exposed animals resulted in a statisti-
cally significant increase (p < 0.01 as deter-
mined by X2 two-way contingency table
analysis) in the MF-exposed animals.
Infiltration data for individual sexes are not
reported. Using the data presented in the
paper, we determined that the difference in
infiltration incidence between MF-exposed
and sham-exposed animals classified as "mod-
erately infiltrated" was also statistically signifi-
cant (p < 0.02) but in the opposite direction
(i.e., the pooled group exposed to the MF
exhibited less infiltration than sham-exposed
controls). This analysis suggests that there
was a relatively high degree of variability
among the various groups and that the posi-
tive results reported by the investigators may
not be biologically significant.
The issue of reproducibility was not
directly addressed in the study. Lymphoma
incidence was enumerated separately in male
and female groups, but since significant dif-
ferences in sensitivity to lymphomagenesis are
known to exist between male and female mice
[see for example, NTP (11), McCormick
et al. (12), and Boorman et al. (13)], the use
of different sex groups cannot serve as a
rough internal check on consistency. Further,
interpretation of the metastatic infiltration
results is complicated by the fact that data
from males and females were pooled rather
than reported separately.
We previously indicated (1) the negative
experiment ofSvedenst'al and Holmberg (75)
did not satisfy several quality control criteria
and is difficult to evaluate. Despite the fact
that the studies of Shen et al. (84) and
Babbitt et al. (15) employed similar MF
exposures (50-Hz, 1 mT and 60-Hz,
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1.41 mT, respectively) and include some
information on metastatic infiltration in liver,
it is difficult to compare the two studies, as
different strains ofmice, different initiators,
and different protocol schedules were
employed. Ofpossible interest, however, is the
observation that an examination of the
histopathology report in Babbitt et al. (15)
does not suggest any increase in lymphocytic
infiltration in the livers ofaged mice exposed
to the MF compared to sham-exposed con-
trols; this contrasts with the effect reported by
Shen etal. (84) for relativelyyoung animals.
LEUKEMIA TRANSPLANT MODELS. LGL
leukemia, also termed mononuclear cell
leukemia, occurs spontaneously and at rela-
tively high and variable frequencies in aged
male F344 Fischer rats. A transplant model
employing passaged LGL cells has been well
described. For recent reviews, see Sasser et al.
(81) and McCann et al. (1).
Although a number of chemicals have
been associated with significant decreases in
the spontaneous incidence ofLGL leukemia
in aged Fischer rats (97,98) and with
decreases in the rate ofonset ofleukemia in
transplant recipients in the LGL transplant
model (99), the ability of this system to
detect leukemogens or co-leukemogens is less
certain. In our previous review (1) we dis-
cussed experiments ofDieter and colleagues
(100) and suggested that their report of
enhancement effects may not be definitive.
More recently, Anderson et al. (101) exam-
ined trichlorophenol, one ofthe agents Dieter
et al. reported as enhancing the disease
process, as well as the known leukemogens
benzene and ionizing radiation (5 Gy) for
their ability to enhance the progression of
LGL leukemia in transplant recipients. Daily
administration of trichlorophenol had no
effect on disease progression; benzene
appeared to delay the onset ofleukemia by
about 6 weeks; and ionizing radiation resulted
in small but statistically significant increases in
some disease parameters. These results suggest
that the ability ofthe LGL transplant system
to detect any given co-leukemogenic agent is
uncertain. Therefore, while the experiments of
Anderson, Sasser, and colleagues (79-82,101)
appear to be well done, the significance of
the results with respect to whether MFs have
any leukemogenic potential is uncertain.
Below, we review the experiments conducted
by this group.
In our previous review (1) we included
preliminary negative results from this group,
which were available in abstract form
(102,103). As discussed above, since our
review was published these experiments have
been completed. Some of the results have
been published in peer-reviewed format
(81,82), and the complete study results are
available in report form (79,80,101). These
experiments were all conducted according to
GLP, and their progress was periodically
reviewed by an independent auditor.
Engineering aspects of the study were also
independently reviewed by the National
Institute ofStandards andTechnology.
As shown in Table 2, two experiments
were conducted. The first experiment
(80-82) involving a total of 504 animals
included chronic 18-week exposure to con-
tinuous, linearly polarized MFs (60 Hz, 1
mT). This experiment involved four treat-
ment groups including the MF-exposed ani-
mals, a sham-exposed control group, ambient
controls, and a positive control group that
received 5-Gy whole-body irradiation. At the
initiation ofMF or sham field exposure, all
animals received an inoculum of2.2 x 107
cells intraperitoneally (i.p.). The progression
ofleukemia in transplant recipients was mon-
itored by palpation of the spleen and by
repeated bleeding of 18 animals in each
group at weeks 0, 2, 4, 5, 6, 7, 8, and 10 fol-
lowing injection and the initiation of expo-
sure. Hematologic parameters monitored
included numbers of red and white blood
cells, numbers ofLGL cells, and hemoglobin
concentration. These 18 animals per MF
treatment group were also followed to their
spontaneous deaths, which allowed evaluation
ofmortality (81). Additionally, serial sacrifice
was performed on 108 additional animals in
each ofthe four groups at weeks 5, 6, 7, 8, 9,
and 11 (18 animals in each group were sacri-
ficed at each time point) for additional mor-
phologic, hematologic, and histopathologic
evaluation (82). Investigators report that sig-
nificant or consistent differences between
exposed and control groups were not observed
in any experimental parameter, whereas con-
sistent statistically significant differences were
observed for the positive control group in
most experimental parameters.
In a second experiment (79) involving a
total of 144 animals, two additional variables
were examined (Table 2): the inoculum size
(2.2 x 107 vs 2.2 x 106 cells per rat, i.p.);
and chronic exposure (20 hr/day, 7
days/week for 22 weeks) to a continuous
(linearly polarized) or intermittent (3 min
on/off) MF (60 Hz, 1 mT). This experiment
also included ambient and positive controls
as in the experiments discussed above. Sham-
exposed controls were not included in this
study based on historical MF studies that
demonstrated no significant difference
between sham and ambient control groups.
All animals were bled weekly: rats injected
with 2.2 x 107 cells were bled from weeks 5
to 12, and animals injected with 2.2 x 106
cells were bled from weeks 6 to 16.
Additionally, body weight and splenomegaly
were monitored throughout the study and
spleen weights were determined at necropsy.
The experiment employing conditions of
a cell inoculum of2.2 x 107 and exposure to
continuous fields represents a replication of
the first experiment discussed above (80-82).
As in the first study, no significant differences
were noted between ambient and MF-
exposed groups in anyneoplastic parameter.
A comparison of results in these two
experiments employing inocula of2.2 x 107
does, however, indicate other differences that
illustrate the interexperimental variability of
this system. First, the rate ofdisease develop-
ment appears to be similar as measured by the
time of onset of palpable splenomegaly
(approximately 7 weeks in both sets ofexperi-
ments) but appears to be quite different as
measured by mortality. For the positive con-
trols, 50% survival occurred at approximately
15 weeks in the first experiment (80-82) and
at approximately 23 weeks in the second
experiment (79). Second, the first experiment
(80-82) demonstrated a significantly more
rapid decline in survival ofthe positive con-
trols compared to all other experimental
groups, whereas the replication experiment
(79) did not indicate anysignificant enhance-
ment in the mortality rate ofthe positive con-
trols over those of the other experimental
groups. In contrast, the hematologic parame-
ters measured in both sets of experiments
demonstrate observable effects ofthe radia-
tion exposure in the positive controls
compared to the other experimental groups.
For the groups exposed to intermittent
MFs (1 mT off/on at 3-min intervals) that
received 2.2 x 107 cell inocula, statistically sig-
nificant differences between the MF-exposed
group and ambient controls were observed in
virtually all hematologic parameters moni-
tored (number ofred blood cells, hemoglobin
concentration, packed cell volume, nucleated
red blood cells, white blood cells, LGL cells,
and lymphocytes). The direction ofthe differ-
encewas consistent, suggestingan earlier onset
ofdisease in the MF-exposed group. Similar
effects were not observed in the group
receiving thesmaller inoculum.
Interpretation ofthis result is complex.
First, group sizes were modest (18 animals
per group), suggesting the possibility ofvari-
ability in the outcome. Second, as the investi-
gators point out, the lack ofconsistency in
results between the two experiments involv-
ing different inocula could be an argument
for the absence of a real effect. However,
reduced sensitivity to MF effects due to
slower progression ofthe disease in animals
receiving the smaller inoculum cannot be
ruled out. Third, the differences observed
were statistically significant only ifthe data
were combined over the time course ofthe
disease progression. However, relatively small
and inconsistent differences in disease
parameters were observed in this system for
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irradiation, a known potent leukemogen.
Thus, if MFs were a leukemogen or co-
leukemogen ofweak to moderate potency, the
results observedwould notbe unexpected.
In summary, the results ofthis study do
not rule out the possibility that chronic expo-
sure of rats inoculated with 2.2 x 107 LGL
cells to a 60-Hz, 1 mT intermittent (3 sec
on/off) field may result in enhancement of
LGLleukemia growth in transplant recipients.
The factors suggesting that the intermittent
MF may have some enhancing effect are first,
the high quality ofthe study, particularly with
respect to inclusion ofappropriate controls
and a relatively large number ofmonitored
disease parameters, aswell as adetailed presen-
tation ofresults; second, the consistency ofthe
direction ofthe effect; and third, the fact that
a large number ofhematologic parameters
demonstrated an apparent enhancement
effect. This third factor must, however, be
tempered with the caveat that biologic varia-
tion in one hematologic parameter might be
expected to affectotherparameters aswell.
TESTS IN LYMPHOMA/LEUKEMIA-PRONE
MOUSE STRAINS. Transgenic models. A large
and increasing number oftransgenic mouse
models are now available for the study of
oncogenesis. For general reviews see Seldin
(104) and Adams and Cory (105). Several
transgenic models, including ap53def system
(discussed below), are currently undergoing
multilaboratory validation as alternative car-
cinogen testing methods (106,107). Two
transgenic mouse systems have been used to
test for possible effects of EMF on carcino-
genesis. These are model systems involving
the oncogenespim-1 andp53f
For recent reviews of the function and
regulation ofpim-1, see Hoover et al. (108),
Jonkers and Berns (109), and Berns et al.
(110). In the transgenic models involving the
pim oncogene that have been used to test for
possible effects of EMF (77,83), pim-1 is
linked to the immunoglobulin heavy chain
enhancer(Eg). This linkage mimics the chro-
mosomal translocation associated with lym-
phoid tumors and promotes transgene
expression in both T and B cells (105,111).
Ej-pim-1 mice exhibit a 5-10% spontaneous
incidence ofT-cell lymphomas that appear
early in life (at approximately 7 months of
age) (90). After 10 months ofage, nonlym-
phoblastic lymphomas predominate
(83,112). These mice are susceptible to
point-mutation-inducing genotoxic carcino-
gens such as ENU (113,114) and to other
genotoxic carcinogens including X-irradiation
(90), benzo[a]pyrene (115), and the hetero-
cyclic amine 2-amino-1-methyl-6-phenyli-
midazo-[4,5-b]pyridine (116). Most
lymphomas induced in this system by ENU
are lymphoblastic lymphomas (117).
Nongenotoxic lymphomagenic agents tested
in the system, such as benzene (118) and
TPA (115), have been negative. Ep-pim-1
mice have also been used to test for possible
effects of microwave frequency electro-
magnetic fields (112).
The E1i-pim-1 system employing ENU as
inducer has been demonstrated to detect
inhibitory effects ofone oftwo agents tested
that are known to have a broad spectrum of
chemopreventive activity in other animal
model systems (119). To our knowledge, the
system employing ENU has not been used to
test for promoters or other agents that enhance
the post-initiation stages ofcarcinogenesis.
The function and regulation ofp53 have
been comprehensively reviewed (120-124).
For discussion of the use ofp53 transgenic
models in the study ofmultistep lymphoma-
genesis, see Seldin (104). Mice homozygous
for the p53 null allele (knockout mice that
lack the p53 protein entirely) are highly sus-
ceptible to T-cell lymphoma. However, in
these homozygous knockout mice, sponta-
neous tumors develop so rapidly that the
detection of co-carcinogenic or late-stage
effects oftest agents is not feasible (104). The
p53systemp53def, which has been used to test
for possible carcinogenic enhancement effects
ofEMF (77), uses mice heterozygous for the
p53 null allele (p53Y-). Malignant lym-
phomas also occur spontaneously in heterozy-
gotes. In animals less than one year ofage, few
tumors are observed, but among these, tumors
of the hematopoietic system predominate
(77). Over a longer time period, osteosarco-
mas and soft-tissue sarcomas develop sponta-
neously, and these tumors are similar to those
commonlyobserved in children (76).
In thep53defsystem, since tumors do not
usually develop until the mice reach one year
ofage, detection ofeffects of treatment with
potential co-carcinogens is feasible (76).In
fact, several known carcinogens such as
dimethylnitrosamine (76,125), ionizing radi-
ation (126), p-cresidine, and 4-vinyl-1-cyclo-
hexene diepoxide (127) have been observed
to accelerate development ofvarious neo-
plasms in this model. A 50-chemical multi-
laboratory study is currently in progress to
further validate the sensitivity and specificity
of thep53def test system (106). It has been
suggested that thep53Jef system may provide
some advantage for detection ofcarcinogenic
potential relevant to human risk by its appar-
ent insensitivity to rat or mouse strain-specific
carcinogens (128,129).
A possible limitation for detection of
potential co-carcinogenic effects of EMF is
that thep53defsystem has failed to respond to
the nonmutagenic carcinogens tested so far
(127,129). In fact, recently it was suggested
that thep53def system be used solely for test-
ing for the potential carcinogenicity ofagents
with evidence of genotoxic potential (130).
This caveat is ofparticular relevance to the
interpretation ofresults obtained in tests of
EMF, which are generally considered to lack
genotoxic potential [recently reviewed by
McCann et al. (10)].
Tests ofEMF Using thepim-1 andp53def
Systems. At the time ofour previous review
(1), negative results of tests of MFs in the
p53defandpim-1 systems by McCormick and
colleagues had been reported in abstract form
(131). More completely described results of
these experiments are now available (77).
In this report (77), experiments using the
p53def system involved exposure (18.5 hr/day
for 23 weeks) of male and female mice (30
per sex group) to 60-Hz, 1-mT continuous,
linearly polarized, transient-free MFs. The
experiment was terminated at the end ofthe
exposure period. Mortality, lymphoma inci-
dence, and the incidence ofother neoplastic
lesions (determined by partial necropsy) were
reported. All aspects ofthe protocol are thor-
oughly described and the study conforms to
data quality criteria.
Over the 23-week period of the
experiment, statistically significant changes in
mortality or tumor incidence were not
observed in animals exposed to the MF com-
pared to sham-exposed controls. Investigators
conclude that these data do not support the
hypothesis that MFs are a significant risk
factor for hematopoietic neoplasia.
Experiments were also conducted concur-
rently using the Ep-pim-1 system with ENU
(25 mg/kg, lx, i.p.) as inducer 1 day prior to
MF exposure. These experiments also
involved 23-week exposures (18.5 hr/day) of
male and female mice (30 per sex group), and
were also terminated at 23 weeks. However,
in the experiments using the Ep-pim-1 sys-
tem, a broader range of MF intensities were
examined. These included continuous (60-
Hz, 2 pT, 0.2 mT, and 1 mT linearly polar-
ized, transient free) as well as intermittent
(60-Hz, 1 mT, 1 hr on/off) fields. This exper-
iment was similar to that described above for
the p53def system. Virtually all neoplastic
lesions identified were lymphomas.
Investigators report that lymphoma incidence
in male mice exposed to continuous 1 mT
fields was signficantly (p < 0.05) reduced
from that in sex-matched sham-exposed con-
trols, and that significant differences were not
observed in any other parameter.
Harris et al. (83) exposed groups of
female mice (approx. 100/group) to 50-Hz
MFs for 20 hr/day up to 18 months. MFs
were either continuous (1 pT, 100 pT, and 1
mT) or pulsed (1 mT, 15 min on/off).
Controls included wild-type and Ep-pim-1
sham-exposed controls and a positive control
group ofEp-pim-1 mice unexposed to the
MF but treated with ENU (50 mg/kg, i.p.).
A full necropsy was performed on all mice
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indicating clinical signs of disease by
18 months after the initiation ofexposure and
a histopathologic analysis was conducted on a
wide range of tissues. Immunofluorescence
and immunohistochemical techniques were
used to phenotype representative lymphomas.
The incidence oflymphoblastic and non-
lymphoblastic lymphomas was determined for
those animals dying over the course of the
experiment and the cumulative incidence of
the different types oflymphomas identified by
immunophenotyping on representative ani-
malswas also reported.
No statistically significant differences or
suggestive trends were noted for any MF-
exposed group in any parameter compared to
Eji-pim-1 sham-exposed controls. However,
investigators reported a statistically significant
(p < 0.001) increase in a lethal nontumor end
point, a transgene-dependent renal glomeru-
lar disease, in the group ofmice exposed to
continuous 1 mT fields.
Except for the reservations discussed
below, this experiment satisfies basic quality
control criteria. In addition, both the expo-
sure and pathology phases ofthe study were
conducted under blinded conditions, and the
histopathology results were independently
evaluated. The significance ofthis study as an
indication oflack ofcarcinogenic potential of
EMF is uncertain for several reasons. First,
investigators did not examine survivors not
showing clinical signs of disease after 18
months ofexposure for evidence ofsubclini-
cal disease. This omission could have limited
the sensitivity ofthe analysis for detection of
a late enhancement effect. Second, as dis-
cussed above, to the extent that known non-
genotoxic carcinogens have been tested in this
system, they have been negative. Thus, it is
possible that a nongenotoxic agent such as
EMF (10) might not be detected. Third,
investigators indicate that approximately 13%
ofthe 293 animals in the study that died or
exhibited clinical signs ofdisease within 18
months were undiagnosable because ofautol-
ysis or other causes. This animal loss may
raise some general concerns about quality
standards applied in the study. However, it
may not otherwise bring into question the
negative results reported, since investigators
report that these undiagnosable animals were
distributed roughly equally throughout the
control and exposure groups. Even if it is
assumed that neoplastic disease in these undi-
agnosable animals only occurred in one ofthe
MF-exposed groups, the resulting increase in
tumor incidence would not be large enough
to alter the basic condusion ofthe study.
The experiments employing the p53def
and E1-pim-1 systems reviewed here are sub-
stantially negative. Although McCormick et
al. (77) and Harris et al. (83) used the
Epi-pim-1 system and both employed similar
frequencies and MF intensities, the two
experiments are not comparable because all
test groups employed by McCormick et al.
(77) were pretreated with ENU, and Harris
et al. (83) did not employ ENU in any
groups exposed to MFs.
Leukemia-prone AKR mice. In an older
study that we have not previously reviewed,
Bellosi (85) exposed the leukemia-prone
AKR strain of mice to MFs. The fields are
described as pulsed, modulated at either 12
Hz or 460 Hz, and of6 mT intensity. More
precise characterization ofthe pulsed field is
not provided. Exposure was for 30 min twice
weekly and was continued for five genera-
tions. Group sizes were maintained at
between 20 and 30 animals throughout the
experiment. Procedures used to maintain
group sizes across five generations are not
specified. Control groups were most likely
sham-exposed, but this is not precisely indi-
cated in the report. Survival, spleen weight,
and thymus weight were reported as averages
for each generation group, presumably
including results from both male and female
animals. Investigators report no statistically
significant differences between exposed and
control groups in anyofthe three parameters.
Interpretation ofthese results is complicated
by the fact that different numbers ofanimals
were used to determine survival on the one
hand and spleen and thymus weights on the
other; criteria used to select animals for
determination ofspleen and thymus weights
are notspecified.
The significance ofthe negative results of
this study are questionable. In addition to the
quality control concerns indicated above, the
very high incidence ofleukemia in the AKR
strain ofmice suggests that any enhancement
effect of MF exposure on the neoplastic
process, particularly a weak effect, might be
difficult to discern.
Assaysforpromotion ofbrain cancer in
rodents. At the time of our previous review
(1), ongoing studies ofpossible effects of
EMF exposure on promotion ofbrain cancer
in rodents had not been completed (132).
Reports of tests in two rodent systems are
now available and are reviewed below.
Mandeville and colleagues (133) test for pos-
sible promotion effects using the ENU
transplacental model in rats. Babbitt and col-
leagues [discussed by the EMF RAPID
Working Group (3)] test for promotion
effects using the split-dose ionizing radiation
model in mice.
THE ENU TRANSPLACENTAL MODEL. For
reviews ofthe ENU transplacental model, see
Peterson et al. (134), Berleur and Cordier
(135), Inskip et al. (136), and Maekawa and
Mitsumori (137), as well as our previous dis-
cussion (1). Two promoters known to
enhance the development of neoplasia in
other model systems, TPA and zinc acetate,
have been reported to enhance the develop-
ment of neurogenic tumors in the ENU
transplacental model (138,139). These results
have not been considered definitive, however,
because of the small numbers of animals
tested (140). Hexachlorophane, a potential
promoter ofbrain cancer known to produce
astrocyte hypertrophy in the brain (140), did
not promote brain cancer in this model, nor
did several other agents known to promote
neoplasia in other model systems. These
agents include phenobarbital (141), chronic
stress (142), X-irradiation (143), and
methylazoxymethanol (144). We are
unaware of other promoters tested in the
ENU transplacental model. This system has
also recently been used to test for possible
effects of microwave frequency electro-
magnetic fields (145).
Mandeville and colleagues (133)
monitored for potential effects of chronic
exposure to MFs (60-Hz, 2 pT, 20 pT, 200
PT, and 2 mT) on mortality and the develop-
ment of neurogenic tumors in offspring of
F344/N female rats initiated transplacentally
with ENU. Specifically, pregnant rats were
initiated with ENU (5 mg/kg, i.p., on day 18
ofgestation) and continuous exposure to MFs
begun 48 hr following treatment with ENU.
Each experimental group was comprised of50
female offspring. Control groups included a
saline-injected group without ENU treatment
or MF exposure, an ENU-treated control
group without MF exposure, an ENU-treated
control group sham-exposed to the MF, and
an ENU-treated positive control group receiv-
ing TPA [10 pg/kg, i.p. (139)] on days 19-21
ofgestation and every 15 days starting at day
14 after birth and throughout the study).
Animals were monitored throughout the
study for weight loss, mortality, and clinical
signs ofdisease. A complete histopathologic
examination ofbrain, cranial nerves, spinal
cord tissues, and major organs was conducted
on all animals. The experiment was termi-
nated when surviving offspring reached 65
weeks ofage. The only statistically significant
differences observed were for total incidence
ofneurogenic tumors (induding glial tumors
of the central nervous system and
Schwannomas ofthe peripheral nervous sys-
tem) in the positive controls (ENU+TPA)
compared to the group exposed to ENU only
(i.e., no sham or MF exposure) (p < 0.05). No
statistically significant differences were
observed when tumor incidence in each MF-
exposed group was compared to the ENU-
treatedsham-exposed control.
Aside from the variability in tumor
incidence among control groups discussed
below, this study satisfies quality control cri-
teria. In addition, clinical observations and
pathologic evaluations were conducted under
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blinded conditions and according to GLP.
The exposure system and pathology evalua-
tions were validated by independent audit
and the pathology slides were reviewed by a
panel ofpathologists.
The analysis ofthis study is complicated
because the overall incidence of neurogenic
tumors differed considerably between the
unexposed ENU control and the sham-
exposed ENU control (38 and 60%, respec-
tively). This difference is statistically
significant (p < 0.05) but most likely reflects
inherent variability in the system rather than
a biologic effect. Since all the experimental
groups were concurrent, the difference
between these two control groups also sug-
gests that a statistical comparison in which
the two ENU controls (unexposed and sham-
exposed) are combined is well justified. In
fact, a X2 two-way contingency table analysis
indicates that the effect observed in the
ENU+TPA control is not statistically signifi-
cant (p = 0.33) when the comparison is made
to the combined unexposed and sham-
exposed ENU controls. It should also be
noted that total neurogenic tumor incidence
in the ENU + 20 pT-exposed group is almost
identical to that of the ENU+TPA control
(28/50 vs 29/50) and approaches significance
(p = 0.07) when compared to the unexposed
ENU control.
In summary, results ofthis study do not
provide any evidence that MFs promote
neurogenic tumors in the ENU transplacental
system, although the assay has limited sensi-
tivity due to the variability among control
groups. The significance of the negative
results ofthis study must also be taken in the
context ofthe limited information available
on the promotion ofneurogenic tumors in
this system.
THE SPLIT-DOSE IONIZING RADIATION
MODEL. This model, as developed by Kaplan
[e.g., see Kaplan and Brown (74)] and dis-
cussed previously (see the section "Lym-
phoma in mice pre-exposed to initiating
agents"), is primarily used to study the devel-
opment ofT-cell lymphomas that do not
involve neural tissues. To our knowledge this
model has not previously been used to study
the promotion of brain cancer. However,
high doses ofionizing radiation are associated
with brain cancer in children [reviewed by
Inskip et al. (136)] and there is some evi-
dence that ionizing radiation induces brain
cancer in monkeys (146). It is therefore pos-
sible that the split-dose irradiation treatment
used in the Kaplan model has some initiating
potential for neurogenic tumors.
Babbitt and colleagues [see discussion by
the EMF RAPID Working Group (3)] exam-
ined this possibility in conjunction with
studies primarilyaimed at using the split-dose
ionizing radiation model to determine
whether chronic exposure to 60-Hz, 1.4-mT
circularly polarized MFs enhanced the devel-
opment ofleukemia/lymphoma in female
C57B1/6 mice (190-380 per group) (15) (see
discussion above in "Lymphoma in mice pre-
exposed to initiatingagents").
Three brain tissue sections-from the
frontal cortex and basal ganglia, the parietal
cortex and thalamus, and the cerebellum and
pons-were included in the histopathologic
analysis conducted on each animal necrop-
sied for the leukemiallymphoma study. Very
few primary brain tumors were identified (a
total of seven in all treatment and control
groups), and these appeared to be randomly
distributed among control and treatment
groups. Thus, the doses ofionizing radiation
used did not appear to induce brain neo-
plasms, nor was there evidence of any neo-
plastic neurogenic effects in any groups also
exposed to MFs.
The study was conducted according to
GLP and satisfies all quality control criteria. In
addition, the exposure and histopathologic
analyses were conducted under blinded condi-
tions, and the histopathologic analysis was
subjected to internal andexternal peer reviews.
This study is primarily ofinterest as a test
ofthe ability ofMFs to induce (as opposed to
promote) brain cancer, and that aspect was
discussed in a previous section ("Tests of
Magnetic Fields in 2-Year, Lifetime, or
Multigeneration Exposure Studies"). Because
in the experiments described in this section
ionizing radiation did not induce brain
tumors, the study cannot properly be consid-
ered a test ofthe potential ofMFs to promote
brain cancer.
Discussion
In this report we have updated and extended
our previous review of tests ofelectric and
magnetic fields in animal model systems
designed to assay for potential carcinogenic
activity. A total of29 new reports were iden-
tified, bringing the total ofcompleted reports
now reviewed to more than 60. These reports
encompass the work ofsome 20 independent
research groups throughout the world.
Roughly one-third of the studies in these
reports employ 2-year/lifetime or multigener-
ation chronic exposure bioassays (14 reports
from 5 independent research groups). The
remainder ofthe studies use mostly shorter-
term bioassays to determine whether EMF
has the potential to modulate postinitiation
stages ofcarcinogenesis. The primary assays
for postinitiation activity used are the rat
mammary carcinoma model (19 reports from
4 independent research groups), the mouse
skin model (15 reports from 6 independent
research groups), and several animal models
of leukemia/lymphoma (15 reports from 5
independent research groups).
As shown in Table 5, for all but two of
the six general model systems reviewed (life-
time or multigeneration exposure studies in
rats or mice; rat mammary carcinoma
model; rat liver focus assay; mouse skin
model; models ofhuman leukemia and lym-
phoma in rats or mice; and brain cancer pro-
motion in rats), both positive and negative
results have been reported.
We have previously discussed the difficul-
ties involved in makingsummaryjudgments as
to positivity or negativity across a number of
EMF test results using the same or similar test
system or across different test systems (10). As
indicated in the section "Quality Assurance
and Reproducibility/Comparability Criteria,"
we have relied on a combination ofdata qual-
ity and independent reproducibility criteria to
assist in makingsummaryjudgments as to pos-
itivityornegativity in each model system.
The results ofapplying data quality and
independent reproducibility criteria to assist
in making summary judgments are indicated
in Table 5. Application ofdata qualitycriteria
results in several modifications ofthe data set.
First, reports appearing only in abstract form
or as in progress have been excluded from the
analysis and do not appear in the table [see
McCann et al. (1) and the body ofthis report
for excluded reports]. Second, studies not
conforming to data quality criteria or charac-
terized by factors potentially invalidating
study results are also excluded from the pri-
mary analysis but are included in parentheses
in the table for information. Reports corre-
sponding to these studies are indicated in
footnote "b". Finally, studies not meeting
quality criteria solely because oflimited infor-
mation presented in reviewed reports are
included with studies meeting all quality cri-
teria and appear in the table in boldface type.
Failure ofthese studies to fully meet quality
criteria, however, is noted in the text.
As shown in Table 5, application ofdata
quality criteria does not have a significant
impact on the distribution of positive and
negative results for any model system. Thus,
both positive and negative results are still
reported for all but two ofthe model systems
reviewed, even after applying quality control
criteria. It should be noted, however, that
studies employing the rigorous GLP standard
were uniformly negative except for the equiv-
ocal finding using the LGL rat leukemia
model.
Applying independent reproducibility
criteria to each model system has a much
more dramatic impact on the dataset. As
recently pointed out by the NRC (6), there
unfortunately have been very few attempts to
construct precisely replicated independent
data sets for EMF tests in any system. We
have relied previously on a criterion ofrough
reproducibility to assist in making summary
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Table 5. Combined summary of review results from McCann et al. (1) and from the current review.a
Number of
Total number studies reporting Criterion for rough Number of studies Criterion for rough
of completed statistically significant reproducibility reporting uniformly reproducibility
Animal model system studies reviewedb positive results satisfied? (Y,N,J)c negative results satisfied? (Y, N, ((c
Lifetime or multigeneration 4(1) 1 (1) N 3 Y
exposure studies in rats or mice
Rat mammary carcinoma model 10(2)d 6(0) N, 5(1) N, le
Rat liverfocus assay 2 0 2 N
Mouse skin model
Promotion 4(1)f 0 (1) 4 Y
Co-promotion 6 3 N 3 Y
Models of human leukemia 7 (3) 2 N 5(3) N,l9
and lymphoma in rats or mice
Brain cancer promotion in rats 1 0 1
"The table includes results of tests using ac fields only. bStudy refers to a set of experiments conducted concurrently. Thus, a study may include one or more exposure or protocol conditions. The counting
method we have used is biased toward positive results in that if any ofthe experiments comprising a study are positive, we counted the study as positive. Since a study may be reported in more than one
publication, the numberofstudies does notcorrespond to the numberof reports reviewed. In progress studies and studies reported only in abstractform are not included in the table. Studies roughly satis-
fying data quality criteria are in boldface; studies not satisfying criteria are in parentheses. Studies not satisfying quality criteria solely because of lack of information in the report are included as roughly satisfying criteria. The reports describing studies included in the table are: lifetime or multigeneration exposure studies in rats or mice (11-17); rat mammary carcinoma model (25-35,38,154-156); rat
liver focus assay (157,158); mouse skin model (48-50,52-54,56,58,59,159); models of human leukemia and lymphoma in rats or mice (15,75,77-85); brain cancer promotion in rats (133). Studies not
roughly satisfying quality criteria are as follows. lifetime or multigeneration studies: Fam and Mikhail (17); rat mammary carcinoma model: NTP-first 13-week study (33,34); Ekstrom et al. (30); mouse
skin model: Rannug etal. (48); models of human leukemia in rats or mice: Svedenstal and Holmberg (75); Thomson et al. (78); Bellossi (85). cY =Yes; N = No; =criterion satisfied forintralaboratory replic- ability. dThe NTP report (33-35) consists of three experiments, two of which were conducted concurrently (the first 13-week experiment and the 26-week experiment). We have therefore counted the NTP
report as two studies. "Both the second 13-week study and the 26-week study conducted by the NTP (33-35) were negative. 'the Rannug et al. (48) study consisted of concurrent experiments involving eithercontinuous or intermittent exposures to MFs and, as indicated in footnote "b," would therefore normally be counted as a single study. However, because onlyexperiments involving continuous expo- sures satisfied quality criteria, we have entered the results of Rannug et al. (48) as two studies. 9The two experiments of Anderson, Sasser and colleagues involving a cell inoculum of 2.2 x 107 (79-82) satisfy the criterion for intralaboratory replicability.
judgments about the positivity or negativity
ofEMF test results in genotoxicity assay sys-
tems (10). Here we apply the rough repro-
ducibility criterion to the available test results
from animal model systems.
As shown in Table 5, among studies
roughly satisfying quality criteria, the crite-
rion for independent reproducibility is not
satisfied for any positive results; it is satisfied,
however, for negative results in lifetime expo-
sure studies in rats and mice and for both
promotion and co-promotion assays in the
mouse skin model. The criterion for intra-
laboratory reproducibility is satisfied for both
positive and negative results using the rat
mammary carcinoma model (i.e., results of
independent replications are contradictory)
and for negative results in studies using the
LGL rat leukemia model.
The reproducibility analysis is complex
and critically important in making summary
judgments among the results reviewed. Table
6 lists, for each model system reviewed, pairs
of test results that were obtained indepen-
dently by different laboratories or that were
results of nonconcurrent intralaboratory
replication studies. Each pair ofstudies listed
conforms to the criterion of rough repro-
ducibility (see "Quality Assurance and
Reproducibility/Comparability Criteria").
The studies listed in Table 6 also all approxi-
mately satisfy basic quality criteria as dis-
cussed above (i.e., they appear in boldface in
Table 5).
As shown, twelve pairs ofstudies satisfy
rough reproducibility criteria. These include
four pairs of lifetime or multigeneration
exposure studies [(11-13) vs (16), (11-13) vs
(14), (11-13) vs (15), and (14) vs (16)]; four
pairs ofstudies using the rat mammary carci-
noma promotion model [(29) vs (28), (32,38)
vs (25-27), (33-35) vs (25,26,32,38), and
(33,34) (the second 13-weekstudy) vs (33,35)
(the 26-week study)]; three pairs ofstudies
using the mouse skin promotion/co-promo-
tion model [(54) vs (58,59), (50) vs (53),
(52,54) vs (50,53)]; and one pairemploying a
mouse leukemia transplant model [(80-82) vs
(79)]. We discuss the results ofthese pairwise
comparisons brieflybelow.
Lifetime orMultigeneration
Exposure Studies
As shown in Table 6, aspects ofthe compre-
hensive 2-year chronic bioassay conducted by
the NTP (11-13) overlap three indepen-
dently conducted long-term chronic bioassays
(14-16), and two ofthe latter three studies
also have overlapping aspects (14,16). Four
pairwise comparisons are indicated in Table 6:
a) results obtained in male F344 rats at over-
lapping exposures spanning a range of0.2-5
mT (continuous) [this comparison involves
the NTP bioassay (11-13) and the study of
Yasui et al. (16)]; b) results obtained in
female F344 rats at overlapping exposures
spanning a range of0.002-2 mT (continuous)
[this comparison involves the NTP bioassay
(11-13) and the study ofMandeville et al.
(14)]; c) results obtained in female C57B1/6
mice at overlapping exposures spanning a
range of0.2-1.4 mT (continuous) [this com-
parison involves the NTP bioassay (11-13)
and the study ofBabbitt et al. (15)]; and d)
results obtained in female F344 and
F344/DuCrj rats at overlapping exposures
spanning a range of0.2-5 mT (continuous)
[this comparison involves the studies of
Mandeville et al. (14) and Yasui et al. (16)].
The results ofthese four comparisons provide
independently replicated evidence that
chronic exposure to MFs under the conditions
ofthe assays does not result in anystatistically
significant increase in the incidence of: a) any
tumor type in male (two independent assays)
or female (three independent assays) rats; and
b) lymphoid neoplasms in female mice.
RatMammaryCarcinomaModel
For the rat mammary carcinoma promotion
model, four pairwise comparisons are possible,
involving three intralaboratory comparisons
[(29) vs (28), (32,38) vs (25-27), and
(33,34) (the second 13-weekstudy) vs (33,35)
(the 26-week study)], and one independent
replication [(33-35) vs (25,26,32,38)]. Two
ofthe three intralaboratory comparisons con-
firm positive tumor incidence results,
although, as discussed in the text and indicated
in Table 6, there were some differences
between studies comprising both of these
intralaboratory replication study pairs. The
intralaboratory replications conducted by the
NTP were both negative. The independent
replication study ofNTP resulted in negative
results for tumor incidence, which contradicts
the earlier positive reports from the Loscher
group. The NTP 26-week study, however,
found a small but not statistically significant
increase in tumorvolume in all three groups of
MF-exposed animals, not dearly contradicting
the earlier statistically significant finding at
approximately 13 weeks reported by the
L6schergroup (26,38).
Environmental Health Perspectives * Vol 108, Supplement 1 * March 2000 96ANIMAL MODELS AND THE POTENTIAL CARCINOGENIC ACTMTY OF EMFs
Table 6. Reproducibility of positive ornegative results ofcarcinogenesis tests of EMFs in animal model systems.
Studies satisfying Q/A
criteria that are sufficiently Overlapping
comparable for rough exposure Overall judgment as
Testsystem reproducibility analysisa rangecompared to positivity or negativity Comments
Lifetime or multigener- NTP(11-13)vs Yasui et al. (16) 0.2-5 mT, Negative in male rats Neitherthe increased incidence offibroma
ation exposure studies
NTP(11-13) vs Mandeville
et al. ( 14)
NTP (11-13) vs Babbitt et al. (15)
Mandeville et al. (14) vs Yasui
et al. (16)
continuous
0.002-2 mT,
continuous
of s.c. tissue reported byYasui et al.
northe increased incidence ofthyroid
C-cell adenoma and carcinoma reported by
the NTPwere observed in the otherstudy
Negative in female rats
0.2-1.4 mT, Negative for lymphoid neoplasms in
continuous female mice
0.2 mT-5 mT Negative in female rats
Anisimov et al. (29)vs
Beniashvili etal. (28)(intra-
laboratory comparison)
Mevissen et al. (32) and Thun-
Battersby et al. (38)vs Loscher
et al. (25), Baum et al. (26), and
Mevissen et al. (27) (intra-
laboratorycomparison)
NTP (33-35)vs Mevissen etal.
(32), Lischer et al. (25), Baum
et al. (26), and Thun-Battersby
etal. (38)
NTP (33,34) (second 13-wk
study) vs NTP(33,35){26-week
study) (intralaboratory
comparison)
0.002 mT Enhancement ofthe rate of development
of MNU-induced mammary adenocarcinoma
in female rats
0.05-0.1 mT Positive in female rats based on tumor
incidence rates determined bypalpation
0.05-0.5 mT Results contradictory for tumor incidence as
measured by palpation, macroscopically
visible tumors at autopsy, and adeno-
carcinomas
0.1 mTor
0.5 mT
Statisticallysignificantdifferences in tumor
volume reported by Baum et al. (26)were
not observed in the replication study of
Mevissen et al. (32) butwere observed
in the study ofThun-Battersby et al. (38)
Negative
DiGiovanni etal. (54)vs Stuchly
et al. (58) and McLean et al. (59)
Stuchly et al. (50) vs McLean
etal. (53) (intralaboratory
comparison)
Sasser et al. (52) and DiGiovanni
et al. (54) vs McLean et al. (53)
and Stuchly et al. (50)
2 mT The initial positive report of Stuchly et al.
(50) was not reproduced in two subsequent
replications by members ofthe same
research team
2 mT Negative
Animal models of human
leukemia and lymphoma
Leukemia transplant
models
Anderson et al. (80), Sasser et
a). (81), and Morris et al. (82)
vs Anderson etal. (79) (intra-
laboratory comparison)
1 mT Negative for a cell inoculum of 2.2 x 101 Differences between the two experiments
in some non-neoplastic parameters
indicate interexperimental variability
80/A criteria are as specified in the text. Studies approximately conforming to quality criteria are included for comparative purposes. Studies considered to deviate from 0/A criteria or for other reasons
considered to be inappropriate for a comparative analysis (such as available only in abstract form) are as follows. lifetime or multigeneration exposure studies: Fam and Mikhail 117); Kharazi et al. [dis-
cussed bythe RAPID Working Group(311. Rat mammary carcinoma model: Ekstrom et al. (30). Mouse skin model: Byus and Ma(571; McLean et al. (49). Human leukemia/lymphoma models: Svedenstjl and
Holmberg (75); Thomson et al. (78).
Mouse SkinModel
For the mouse skin promotion-co-promotion
model, three pairwise comparisons are indi-
cated in Table 6: one intralaboratory pair-
wise comparison involving an assay for
co-promotion [(50) vs (53)] and two inde-
pendent replication pairs, one involving an
assay for promotion activity [(54) vs
(58,59)] and the other an assay for co-
promotion [(52,54) vs (50,53)]. All these
studies were conducted using the SENCAR
mouse and all involved chronic exposure to
60-Hz, 2-mT (continuous) MFs. All promo-
tion studies were negative, a result confirmed
by both intralaboratory and independent
replication studies (54,58,59). The original
positive co-promotion result reported by
Stuchly et al. (50) was not reproduced in
subsequent intralaboratory replications of
McLean et al. (53) or in the independent
replication study (52,54).
Animal Models ofHuman Leukemia
andLymphoma
Finally, an intralaboratory comparison involv-
ing two studies using the LGL rat leukemia
transplant model [(80-82) vs (79)] indicated
negative results in both assays for chronic
exposures to 60-Hz 1 mT (continuous) MFs.
As indicated in the text and in Table 6, how-
ever, differences between the two experiments
in some non-neoplastic parameters indicate
significant interexperimental variability.
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Rat mammary
carcinoma model
Mouse skin model
Promotion
Co-promotion
2 mT Negative
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Summary of Positivity and
Negativity
Among the 34 studies reviewed in this and
our previous report (1) that we consider
roughly to meet quality criteria, 12 studies
reported positive results and 23 reported uni-
formly negative results. As discussed above,
evidence of independent replication is avail-
able only for negative results in two model
systems (lifetime or multigeneration exposure
studies in rats and mice and promotion-co-
promotion studies using the mouse skin
model). Positive results unconfirmed by inde-
pendent replication have been reported in 12
studies satisfying basic data quality criteria
(see Tables 2 and 5). We discuss each ofthese
positive results briefly below.
Lifetime or multigeneration exposure
studies in rats or mice. The statistically sig-
nificant positive results that form the basis for
the NTP conclusion of equivocal evidence of
carcinogenicity (11) are most likely statistical
artifacts resulting from biologic variability.
This conclusion is strengthened by the failure
ofthis isolated positive result to be confirmed
in asimilar study byYasui et al. (16).
Rat mammary carcinoma model All six
positive studies are from two laboratories,
those of Beniashvili and colleagues and
Loscher and colleagues (see Table 2 and text
for references). While both laboratories have
provided intralaboratory replication studies
confirming their positive results, the only
attempt at independent replication (33-35)
was negative. Unfortunately the study proto-
cols used by Beniashvili and colleagues and
Loscher and colleagues are too dissimilar to
permit direct comparison.
Mouse skin model Ofthe three positive
results obtained using this system, two results
utilized the SENCAR mouse DMBA/TPA
co-promotion system. One ofthese positive
studies (50) was unconfirmed in subsequent
replication attempts performed by members
ofthe same research team. A second positive
result used the same model system but
involved a different neoplastic end point
(49), which precluded direct comparison.
The third positive result was obtained in an
unvalidated assay system employing UV light
as inducer (56). None ofthese studies were
comparable to the others.
Models ofhuman leukemia andlym-
phoma in rats or mice. One ofthe two posi-
tive results in this model type occurred in the
rat LGL transplant assay in a well-docu-
mented study satisfying quality criteria (79).
The other positive result occurred in a mouse
lymphoma assay employing DMBA as
inducer (84); interpretation ofthis result is
not obvious. As indicated above, the result
obtained by Anderson et al. (79) is equivocal
and its interpretation is complex. Because of
the generally high quality of the study,
however, the result is possibly significant.
Conclusions
Results of applying data quality and
reproducibility criteria to the current data
available from in vivo animal carcinogenesis
bioassays strongly indicate that chronic expo-
sure to continuous MFs in the range of
0.002-5 mT is unlikely to result in carcino-
genesis in rats or mice. Although chronic
exposure to MFs appears to be clearly negative
in one promotion assay (the mouse skin
model), results are conflicting in another assay
(the rat mammary carcinoma model), and
unreplicated weakly positive results have been
reported in one treatment group in a third
assay (the rat LGL transplant assay).
Therefore, a weak promoting effect ofMFs
under certain exposure conditions cannot be
ruled out categorically based on available data.
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